Individual data gathered by a Proteus system (therapy, behavior, physiology) together with publically available data may influence overall health risk and health maintenance of the individual. Such data may include individual demographics, prevalence of disease in a particular geography, proximity to health care service centers, performance (outcomes) associated to HCPs (Health care Provider's) in local, proximity to businesses that might influence healthy behavior (health clubs, restaurants, fast-food, grocery stores, parks, etc).
By combining the data, risk can be properly adjusted for the specific patient situation and appropriate resource can be applied to manage the risk appropriately.
The aggregate patient health risk can be more effectively determined by combining Proteus system data (therapeutic regimen and adherence, behavior, engagement, and physiology) together with one or more data elements.
The data listed above may also be used without a Proteus system data to provide an independent risk-score. By combining the data, risk can be properly adjusted for the specific patient situation and appropriate resource can be applied to manage the risk appropriately. The data might be sourced from a combination of direct capture, public data sources and/or privately available systems/sources.
In one aspect, a computer-implemented method is disclosed. The computer-implemented method comprises receiving, by a computer system, ingestible event marker (IEM) system information from a receiver worn by a subject, the IEM system information comprising information associated with ingestion of medication by the subject, wherein the receiver is configured to communicate with the computer system; receiving, by the computer system, contextual information associated with the subject; and calculating, by the computer system, a composite risk score based on the IEM system information and the contextual information associated with the subject.
In one aspect, a computer-implemented method is disclosed. The computer-implemented method comprises receiving, by a computer system, daily data from a subject; calculating, by the computer system, the daily data into a dominant circadian pattern; tracking, by the computer system, daily variations between the daily data and the dominant circadian pattern; and calculating, by the computer system, a distribution of the daily variations; and quantifying, by the computer system, the distribution of the daily variations by differential entropy.
In one aspect, a computer-implemented method is disclosed. The computer-implemented method comprises receiving, by a computer system, daily data from a subject; applying, by the computer system, principal component analysis to the received daily data to determine a dominant mode; determining, by the computer system, a variation between the daily data and the dominant mode; and determining, by the computer system, how many samples of the daily data are above a predetermined threshold.
The foregoing summary is illustrative only and is not intended to be in any way limiting. In addition to the illustrative aspects, aspects, and features described above, further aspects, aspects, and features will become apparent by reference to the drawings and the following detailed description.
The novel features of the aspects described herein are set forth with particularity in the appended claims. The aspects, however, both as to organization and methods of operation may be better understood by reference to the following description, taken in conjunction with the accompanying drawings as follows.
Aspects of the present disclosure include combining individual data gathered by a Proteus system (therapy, behavior, physiology, e.g., as described in greater detail in Appendix A) together with publically available data that might influence overall health risk. Data might include individual demographics, prevalence of disease in a particular geography, proximity to health care service centers, performance (outcomes) associated to HCPs in local, proximity to businesses that might influence healthy behavior (health clubs, restaurants, fast-food, grocery stores, parks, etc).
By combining the data, risk can be properly adjusted for the specific patient situation and appropriate resource can be applied to manage the risk appropriately.
The aggregate patient health risk can be more effectively determined by combining Proteus system data (therapeutic regimen and adherence, behavior, engagement, and physiology) together with one or more of the following data elements:
The data listed above may also be used without a Proteus system data to provide an independent risk-score. By combining the data, risk can be properly adjusted for the specific patient situation and appropriate resource can be applied to manage the risk appropriately. The data might be sourced from a combination of direct capture, public data sources and/or privately available systems/sources.
In one aspect a fusion technique employing Multivariate and Bayesian statistical techniques may be used to determine the combined or composite risk score.
For a basic understanding of the operational details of the Proteus IEM and receiver (patch) system, the reader is directed to
Patch-Derived Data Analytics for Improved Patient Outcomes
One question to be determined is whether feedback from patch-derived data analytics can be utilized to improve outcomes in target patients, such as those suffering from major depressive disorder, bipolar, and/or schizophrenia. In one aspect, the system can identify and quantify individuals at risk using patch-derived data. In a predictive model, the system is configured to determine the likelihood of a patient being hospitalized, being non-compliant, or developing a “new” condition. State monitoring and feedback data can be utilized to determine titration issues, optimization of drug effect, or worsening condition of patient state.
TABLE 1 below, depicts the value of data types in a patient lifecycle management process. The value from a pure data perspective is indicated in the table as Low, Medium, or High.
One question associated with patch-derived data analysis is whether patch-derived data fields can be effective for patient identification and classification. Systems according to the present disclosure provide high classification accuracies using patch-derived data fields and data fusion techniques can be used to enhance performance. The data fields used in the patch-derived data analysis include, without limitation, acceleration, posture, steps, temperature, and heart rate—median and standard deviation. An aggregated data field may be employed to determine whether the patent is asleep.
−90 degrees is completely upright.
Data fusion is the combination of multiple data types into one metric. Fusing multiple data residuals into an “effective residual” can be represented, for example, by the following expression:
DM({right arrow over (x)})=√{square root over ({right arrow over (x)}TC−1{right arrow over (x)})}
Where DM is the “Mahalanobis Distance” and C is the correlation matrix. This expression accounts for the correlations between the data fields to create a “single” residual-type variable that can be used seamlessly with the classification schemes as described in more detail hereinbelow.
A first classification Method 1 classifies the percentage of time the residuals are above a threshold. The time above threshold classification provides an optimal residual threshold that is selected from the training group. The percentage time the residual resides above that threshold is used for classification.
A second classification Method 2 classifies distribution entropy, which is classifying based on features of the data distribution.
In conclusion, high classification accuracies were achieved. Deviations from a unique baseline were calculated for each individual. The deviations or “residuals” appear to possess significant classification power. In addition, the patch-derived data fields worked well for classification. Patch-derived data fields perform as well or better than an aggregate data field for identification and classification of individuals in the study. Finally, data fusion was shown to enhance performance. Fusion of patch-derived data fields provided utility for improving patient classification.
TABLE 2 below, depicts the value of the expanded data types in a patient lifecycle management process. The phone-derived data adds value in the management/maintenance patient state.
PICO: Proteus Indication of Clinical Outcomes—A Risk-Based Approach Based on Therapeutic and Physiologic Data
Accordingly, in one aspect, the present disclosure provides a patch-derived data analytics system to contribute to constructing a health equivalent of a FICO score referred to herein as a PICO score, for example. The PICO score provides an assessment of patient risk and stability across therapeutic areas and enables automated data-driven clinical decision making. This system can provide effective drug therapy management and improved therapeutic program effectiveness at reduced cost. In one aspect, metrics may be derived that are suitable for quantifying the patch-derived data as input to the PICO score. The PICO score system may be employed to predict whether the patient is likely to be hospitalized or non-compliant or developing “new” condition. The PICO score system may provide patient state monitoring and feedback, titration issues, optimization of drug effect, or worsening condition of patient state.
The disclosure now turns briefly to an overview of the patch-derived data analytics for patient risk assessment over two phases. In phase 1, high classification accuracies were achieved with patch-derived data. The “Residual Entropy” method enabled patient classification accuracy of 88.24% as previously described in connection with
In addition to the original phase 1 data set, three new data sets were used and there were some key differences between the data sets. The new data sets consisted entirely for institutionalized subjects with severe health issues. Phase 1 subjects were not institutionalized and the subjects that were not in the neuropsych group were healthy volunteers. The new data sets were collected with an updated version of the patch where many of the sampling rates were higher. These additional data sets are summarized in TABLE 3.
The PICO entropy metric quantifies the variability in the subject's circadian patterns where the dominant circadian patterns are calculated from subject's historical data. The higher the entropy of the variations from the baseline circadian patterns the larger the subject's variability. With reference to
Posture FSLE distributions may be obtained by subject group. The FSLE distributions from aggregated subject group values can be plotted and different therapeutic areas can be clustered together.
The posture FSLE can be used as an input into the PICO score.
Turning now to
Accordingly, patch-derived data is well-suited as a foundation for patient risk quantification. Circadian pattern analysis using posture data is an effective component of a PICO risk score. Risk quantified at the subject group level segmented the groups into appropriate risk groupings. Individual cases illustrated the utility of patch-derived metrics to track subject temporal risk state. Additionally, therapeutic medication adherence data has potential as an additional risk input into PICO. Daily medication taking and timing adherence patterns show prospective added value through individual case analysis. Many cases where medication adherence and circadian pattern abnormalities co-exist.
In connection with data analysis, the system can extend posture-based risk metric procedure to other patch-derived data such as other physiological data (heart rate, temperature, acceleration) and IEM ingestion data. Risk metrics can be modified according to known issues such as when IEM ingestion is not 100% detected and fuzzy data fusion techniques can be employed to merge physiological and therapeutic data types. The therapeutic effect of individual pills (pharmacodynamics) should be accounted for since not all pills can be treated equally.
In connection with risk score training, the system requires subject data with outcomes, including Lifenote project data, and the inclusion of different data types into risk score such as behavioral analytics, passive sensing, contextual data, and patient data.
PICO Risk Score Distributions and Trend Analysis
In accordance with the techniques described herein, a joint circadian pattern (JCP) risk distribution by data set can be developed. In one aspect, four basic groupings Phase 1 Healthy group contains the lowest risk scores (as is expected). Lifenote and Helius groups comprise the middle grouping. Phase 1 Psych and Phase 2 Alpha NonPsych, Hbbread, Hbbrim group together. Alpha Psych group possesses highest risk score distribution.
In accordance with the aforementioned risk scores trend analysis techniques, the present disclosure provides a method of singling out patients for closer scrutiny and/or physician follow-up. A substantial risk score spike may be a temporary occurrence and not necessarily an indicator that a patient is in danger. Observing trends in the risk score time series provides a better indication of a patient's risk state. Other methods including methods of “Partial Trend Analysis” enable the dominant trends in subsets of the time series to be calculated based on minimizing the trend fit error. This result is parametric and may allow more or less detail into the Partial Trend by varying the maximum amount of error allowed. Thus this method can provide both the general trend (with little details) over the entire time series or a set of very short trends that closely approximate the details of the time series. An example is discussed in connection with the next three figures.
In the context of risk magnitude versus risk trend based on a Lifenote data set,
Within the context of risk magnitude versus risk trend based on a risk profile for an individual,
Proteus IEM/Receiver (Patch) System
Various enabling aspects of the IEM are illustrated in
With reference to
In the specific example of the system 2630 combined with the pharmaceutical product, as the product or pill is ingested, the system 2630 is activated. The system 2630 controls conductance to produce a unique current signature that is detected, thereby signifying that the pharmaceutical product has been taken. The system 2630 includes a framework 2632. The framework 2632 is a chassis for the system 2630 and multiple components are attached to, deposited upon, or secured to the framework 2632. In this aspect of the system 2630, a digestible material 2634 is physically associated with the framework 2632. The material 2634 may be chemically deposited on, evaporated onto, secured to, or built-up on the framework all of which may be referred to herein as “deposit” with respect to the framework 2632. The material 2634 is deposited on one side of the framework 2632. The materials of interest that can be used as material 2634 include, but are not limited to: Cu or Cul. The material 2634 is deposited by physical vapor deposition, electrodeposition, or plasma deposition, among other protocols. The material 2634 may be from about 0.05 to about 500 μm thick, such as from about 5 to about 100 μm thick. The shape is controlled by shadow mask deposition, or photolithography and etching. Additionally, even though only one region is shown for depositing the material, each system 2630 may contain two or more electrically unique regions where the material 2634 may be deposited, as desired.
At a different side, which is the opposite side as shown in
Thus, when the system 2630 is in contact with the conducting liquid, a current path, an example is shown in
The voltage potential created between the materials 2634 and 2636 provides the power for operating the system as well as produces the current flow through the conducting fluid and the system. In one aspect, the system operates in direct current mode. In an alternative aspect, the system controls the direction of the current so that the direction of current is reversed in a cyclic manner, similar to alternating current. As the system reaches the conducting fluid or the electrolyte, where the fluid or electrolyte component is provided by a physiological fluid, e.g., stomach acid, the path for current flow between the materials 2634 and 2636 is completed external to the system 2630; the current path through the system 2630 is controlled by the control device 2638. Completion of the current path allows for the current to flow and in turn a receiver can detect the presence of the current and recognize that the system 2630 has been activated and the desired event is occurring or has occurred.
In one aspect, the two materials 2634 and 2636 are similar in function to the two electrodes needed for a direct current power source, such as a battery. The conducting liquid acts as the electrolyte needed to complete the power source. The completed power source described is defined by the physical chemical reaction between the materials 2634 and 2636 of the system 2630 and the surrounding fluids of the body. The completed power source may be viewed as a power source that exploits reverse electrolysis in an ionic or a conductive solution such as gastric fluid, blood, or other bodily fluids and some tissues. Additionally, the environment may be something other than a body and the liquid may be any conducting liquid. For example, the conducting fluid may be salt water or a metallic based paint.
In certain aspects, these two materials are shielded from the surrounding environment by an additional layer of material. Accordingly, when the shield is dissolved and the two dissimilar materials are exposed to the target site, a voltage potential is generated.
Referring again to
Referring now to
Once the control device 2648 is activated or powered up, the control device 2648 can alter conductance between the materials 2644 and 2646. Thus, the control device 2648 is capable of controlling the magnitude of the current through the conducting liquid that surrounds the system 2640. As indicated above with respect to system 2630, a unique current signature that is associated with the system 2640 can be detected by a receiver to mark the activation of the system 2640. In order to increase the “length” of the current path the size of the skirt 2649 is altered. The longer the current path, the easier it may be for the receiver to detect the current.
Referring now to
In one aspect, at the surface of the material 2634, there is chemical reaction between the material 2634 and the surrounding conducting fluid such that mass is released into the conducting fluid. The term “mass” as used herein refers to protons and neutrons that form a substance. One example includes the instant where the material is CuCl and when in contact with the conducting fluid, CuCl becomes Cu (solid) and Cl— in solution. The flow of ions into the conduction fluid is depicted by the ion paths 2650. In a similar manner, there is a chemical reaction between the material 2636 and the surrounding conducting fluid and ions are captured by the material 2636. The release of ions at the material 2634 and capture of ion by the material 2636 is collectively referred to as the ionic exchange. The rate of ionic exchange and, hence the ionic emission rate or flow, is controlled by the control device 2638. The control device 2638 can increase or decrease the rate of ion flow by altering the conductance, which alters the impedance, between the materials 2634 and 2636. Through controlling the ion exchange, the system 2630 can encode information in the ionic exchange process. Thus, the system 2630 uses ionic emission to encode information in the ionic exchange.
The control device 2638 can vary the duration of a fixed ionic exchange rate or current flow magnitude while keeping the rate or magnitude near constant, similar to when the frequency is modulated and the amplitude is constant. Also, the control device 2638 can vary the level of the ionic exchange rate or the magnitude of the current flow while keeping the duration near constant. Thus, using various combinations of changes in duration and altering the rate or magnitude, the control device 2638 encodes information in the current flow or the ionic exchange. For example, the control device 2638 may use, but is not limited to any of the following techniques namely, Binary Phase-Shift Keying (PSK), Frequency modulation, Amplitude modulation, on-off keying, and PSK with on-off keying.
As indicated above, the various aspects disclosed herein, such as systems 2630 and 2640 of
As indicated above, the system, such as system 2630 and 2640, control the conductance between the dissimilar materials and, hence, the rate of ionic exchange or the current flow. Through altering the conductance in a specific manner the system is capable of encoding information in the ionic exchange and the current signature. The ionic exchange or the current signature is used to uniquely identify the specific system. Additionally, the systems 2630 and 2640 are capable of producing various different unique exchanges or signatures and, thus, provide additional information. For example, a second current signature based on a second conductance alteration pattern may be used to provide additional information, which information may be related to the physical environment. To further illustrate, a first current signature may be a very low current state that maintains an oscillator on the chip and a second current signature may be a current state at least a factor of ten higher than the current state associated with the first current signature.
Referring now to
The control module 2662 controls the conductance through logic that alters the overall impedance of the system 2630. The control module 2662 is electrically coupled to the clock 2664. The clock 2664 provides a clock cycle to the control module 2662. Based upon the programmed characteristics of the control module 2662, when a set number of clock cycles have passed, the control module 2662 alters the conductance characteristics between materials 2634 and 2636. This cycle is repeated and thereby the control device 2638 produces a unique current signature characteristic. The control module 2662 is also electrically coupled to the memory 2666. Both the clock 2664 and the memory 2666 are powered by the voltage potential created between the materials 2634 and 2636.
The control module 2662 is also electrically coupled to and in communication with the sensor modules 2672 and 2674. In the aspect shown, the sensor module 2672 is part of the control device 2638 and the sensor module 2674 is a separate component. In alternative aspects, either one of the sensor modules 2672 or 2674 can be used without the other, and the scope of the present disclosure is not limited by the structural or functional location of the sensor modules 2672 or 2674. Additionally, any component of the system 2630 may be functionally or structurally moved, combined, or repositioned without limiting the scope of the present disclosure as claimed. Thus, it is possible to have one single structure, for example a processor, which is designed to perform the functions of all of the following modules: the control module 2662, the clock 2664, the memory 2666, and the sensor module 2672 or 2674. On the other hand, it is also within the scope of the present disclosure to have each of these functional components located in independent structures that are linked electrically and able to communicate.
Referring again to
Referring now to
As indicated above, the control device 2638 can be programmed in advance to output a pre-defined current signature. In another aspect, the system can include a receiver system that can receive programming information when the system is activated. In another aspect, not shown, the switch 2664 and the memory 2666 can be combined into one device.
In addition to the above components, the system 2630 may also include one or other electronic components. Electrical components of interest include, but are not limited to: additional logic and/or memory elements, e.g., in the form of an integrated circuit; a power regulation device, e.g., battery, fuel cell or capacitor; a sensor, a stimulator, etc.; a signal transmission element, e.g., in the form of an antenna, electrode, coil, etc.; a passive element, e.g., an inductor, resistor, etc.
In addition to demodulation, the transbody communication module may include a forward error correction module, which module provides additional gain to combat interference from other unwanted signals and noise. Forward error correction functional modules of interest include those described in PCT Application Serial No. PCT/US2007/024325 published as WO/2008/063626; the disclosure of which is herein incorporated by reference. In some instances, the forward error correction module may employ any convenient protocol, such as Reed-Solomon, Golay, Hamming, BCH, and Turbo protocols to identify and correct (within bounds) decoding errors.
Receivers of the disclosure may further employ a beacon functionality module. In various aspects, the beacon switching module may employ one or more of the following: a beacon wakeup module, a beacon signal module, a wave/frequency module, a multiple frequency module, and a modulated signal module.
The beacon switching module may be associated with beacon communications, e.g., a beacon communication channel, a beacon protocol, etc. For the purpose of the present disclosure, beacons are typically signals sent either as part of a message or to augment a message (sometimes referred to herein as “beacon signals”). The beacons may have well-defined characteristics, such as frequency. Beacons may be detected readily in noisy environments and may be used for a trigger to a sniff circuit, such as described below.
In one aspect, the beacon switching module may comprise the beacon wakeup module, having wakeup functionality. Wakeup functionality generally comprises the functionality to operate in high power modes only during specific times, e.g., short periods for specific purposes, to receive a signal, etc. An important consideration on a receiver portion of a system is that it be of low power. This feature may be advantageous in an implanted receiver, to provide for both small size and to preserve a long-functioning electrical supply from a battery. The beacon switching module enables these advantages by having the receiver operate in a high power mode for very limited periods of time. Short duty cycles of this kind can provide optimal system size and energy draw features.
In practice, the receiver may “wake up” periodically, and at low energy consumption, to perform a “sniff function” via, for example, a sniff circuit. For the purpose of the present application, the term “sniff function” generally refers to a short, low-power function to determine if a transmitter is present. If a transmitter signal is detected by the sniff function, the device may transition to a higher power communication decode mode. If a transmitter signal is not present, the receiver may return, e.g., immediately return, to sleep mode. In this manner, energy is conserved during relatively long periods when a transmitter signal is not present, while high-power capabilities remain available for efficient decode mode operations during the relatively few periods when a transmit signal is present. Several modes, and combination thereof, may be available for operating the sniff circuit. By matching the needs of a particular system to the sniff circuit configuration, an optimized system may be achieved.
Another view of a beacon module is provided in the functional block diagram shown in
Multiplexer 3820 is electrically coupled to both high band pass filter 3830 and low band pass filter 3840. The high and low frequency signal chains provide for programmable gain to cover the desired level or range. In this specific aspect, high band pass filter 3830 passes frequencies in the 10 KHz to 34 KHz band while filtering out noise from out-of-band frequencies. This high frequency band may vary, and may include, for example, a range of 3 KHz to 300 KHz. The passing frequencies are then amplified by amplifier 3832 before being converted into a digital signal by converter 3834 for input into high power processor 3880 (shown as a DSP) which is electrically coupled to the high frequency signal chain.
Low band pass filter 3840 is shown passing lower frequencies in the range of 0.5 Hz to 150 Hz while filtering out out-of-band frequencies. The frequency band may vary, and may include, for example, frequencies less than 300 Hz, such as less than 200 Hz, including less than 150 Hz. The passing frequency signals are amplified by amplifier 3842. Also shown is accelerometer 3850 electrically coupled to second multiplexer 3860. Multiplexer 3860 multiplexes the signals from the accelerometer with the amplified signals from amplifier 3842. The multiplexed signals are then converted to digital signals by converter 3864 which is also electrically coupled to low power processor 3870.
In one aspect, a digital accelerometer (such as one manufactured by Analog Devices), may be implemented in place of accelerometer 3850. Various advantages may be achieved by using a digital accelerometer. For example, because the signals the digital accelerometer would produce signals already in digital format, the digital accelerometer could bypass converter 3864 and electrically couple to the low power microcontroller 3870—in which case multiplexer 3860 would no longer be required. Also, the digital signal may be configured to turn itself on when detecting motion, further conserving power. In addition, continuous step counting may be implemented. The digital accelerometer may include a FIFO buffer to help control the flow of data sent to the low power processor 3870. For instance, data may be buffered in the FIFO until full, at which time the processor may be triggered to turn awaken from an idle state and receive the data.
Low power processor 3870 may be, for example, an MSP430 microcontroller from Texas Instruments. Low power processor 3870 of receiver 3800 maintains the idle state, which as stated earlier, requires minimal current draw—e.g., 10 μA or less, or 1 μA or less.
High power processor 3880 may be, for example, a VC5509 digital signal process from Texas Instruments. The high power processor 3880 performs the signal processing actions during the active state. These actions, as stated earlier, require larger amounts of current than the idle state—e.g., currents of 30 μA or more, such as 50 μA or more—and may include, for example, actions such as scanning for conductively transmitted signals, processing conductively transmitted signals when received, obtaining and/or processing physiological data, etc.
The receiver may include a hardware accelerator module to process data signals. The hardware accelerator module may be implemented instead of, for example, a DSP. Being a more specialized computation unit, it performs aspects of the signal processing algorithm with fewer transistors (less cost and power) compared to the more general purpose DSP. The blocks of hardware may be used to “accelerate” the performance of important specific function(s). Some architectures for hardware accelerators may be “programmable” via microcode or VLIW assembly. In the course of use, their functions may be accessed by calls to function libraries.
The hardware accelerator (HWA) module comprises an HWA input block to receive an input signal that is to be processed and instructions for processing the input signal; and, an HWA processing block to process the input signal according to the received instructions and to generate a resulting output signal. The resulting output signal may be transmitted as needed by an HWA output block.
Also shown in
Wireless communication element 3895 is shown electrically coupled to high power processor 3880 and may include, for example, a BLUETOOTH™ wireless communication transceiver. In one aspect, wireless communication element 3895 is electrically coupled to high power processor 3880. In another aspect, wireless communication element 3895 is electrically coupled to high power processor 3880 and low power processor 3870. Furthermore, wireless communication element 3895 may be implemented to have its own power supply so that it may be turned on and off independently from other components of the receiver—e.g., by a microprocessor.
As stated earlier, for each receiver state, the high power functional block may be cycled between active and inactive states accordingly. Also, for each receiver state, various receiver elements (such as circuit blocks, power domains within processor, etc.) of a receiver may be configured to independently cycle from on and off by the power supply module. Therefore, the receiver may have different configurations for each state to achieve power efficiency.
An example of a system of the disclosure is shown in
The body-associated personal communicator 1004 may comprise any number of distinct physiologic parameter or biomarker collecting and/or sensing capabilities. The number of distinct parameters or biomarker collecting and/or sensing capabilities may vary e.g., one or more, two or more, three or more, four or more, five or more, ten or more, and so on. In certain configurations, the body-associated personal communicator 1004 comprises one or more active components that are able to dynamically monitor and record individual physiologic parameters and/or biomarkers associated with the living subject 1002. Such components include, without limitation, sensors, electronic recording devices, processors, memory, communication components. In one aspect, the body-associated personal communicator 1004 may include an on-board battery to supply electrical power to the active components. The physiologic parameter or biomarker sensing abilities may include sensing cardio-data, including heart rate, (ECG, and the like, respiration rate, temperature, pressure, chemical composition of fluid, e.g., analyte in blood, fluid state, blood flow rate, physical activity, sleep, accelerometer motion data, without limitation, for example.
In one aspect, the body-associated personal communicator 1004 provides specific information about the physiologic state of the subject 1002. In another aspect, some of this information may be derived from sensors embedded in the body-associated personal communicator 1004. The subject 1002 may obtain the body-associated personal communicator 1004 with a prescription, for example, and then wear the body-associated personal communicator 1004 for a prescribed period, e.g., hours, days, weeks, months, years.
In one aspect, the body-associated personal communicator 1004 includes, is configured to (a) monitor and record individual physiology, e.g., physical activity, heart rate, respiration, temperature, sleep, etc., of the living subject 1002 and (b) communicate these parameters beyond the body of the living subject 1002 to other client devices, e.g., mobile phones, computers, internet servers, etc., in order to (c) enable support and collaboration for fitness, wellbeing, disease management, sport, entertainment, gaming, and other applications on a social media platform. A challenge for such body-associated personal communicators 104 is creating a compelling rationale for the individual 1002 to wear or use the body-associated personal communicator 1004 on a continuous basis—for example, to apply an adhesive bandage-based body-associated personal communicator 1004 to their skin for weeks, months and potentially years and accept the possibility of its inconveniences and limitations, such as (i) potential skin irritation, (ii) the burden of frequent application and removal, and (iii) a feeling of intrusiveness into the wearer's daily life. An opportunity for the personal communicator 1004 is to exploit fundamental “intimacy” advantages they have over other sensor-enabled and communication devices that are not worn on or in the body—a body-associated personal communicator 1004 interface with the individual 1002 is by definition highly personal and tangible, with the ability to have private, communication between the individual and the personal communicator (leveraging physical, tactile “body language” or other signals), where the communication is substantially undetectable by others. In this manner, the body-associated personal communicator 1004 may enable product and service possibilities not feasible with other approaches. The body language opportunity seeks to overcome at least some of the challenges and burdens of the body-associated personal communicator 1004 to create a compelling rationale to make the body-associated personal communicator 1004 as indispensable to a consumer as the mobile phone as an extension of their mind and body. In one aspect, discreet communications between the body-associated personal communicator 1004 and the living subject 1002 can be auditory via a small earpiece placed inside the ear canal, or visual via images projected on specialized eye glasses worn by living subject 1002. In other aspects, discreet modes of communication between the living subject 1002 and the personal communicator 1004 include, without limitation, visual, auditory, vibratory, tactile, olfactory, and taste as described in the form of illustrative examples hereinbelow.
In one aspect, the body-associated personal communicator 1004, for example a sensor patch that adheres to the skin of an individual such as the living subject 1002, communicates with its wearer by sending and receiving tactile or other signals. The default settings may be modified such that the body-associated personal communicator 1004 discreetly vibrates or pulses in a specific manner or pattern, e.g., time or space based, to remind the subject 1002 of important events or to communicate important personalized messages to the wearer. The default settings also may be modified such that the subject 1002 can transmit and record meaningful inputs and messages to the body-associated personal communicator 1004 by communicating a simple language of finger taps, jiggles, scratches or other physical inputs initiated by the subject 1002. Through the body-associated personal communicator 1004 communications architecture, e.g., a BLUETOOTH™ or other communication links to other devices beyond the body, the composite set of sensed physiology, tactile inputs, and outputs can be transmitted to other individuals, groups, caregivers, and related products, e.g., online games, of the subject's 1002 choosing via the external local node 1006, network 1008, and/or the remote node 1010. The features of the body-associated personal communicator 1004 are based on a sustained behavior change mechanism and it increases the value and potential of body-associated personal communicators 1004 and the likelihood that consumers will seek out, use, and benefit from such body-associated personal communicators 1004.
In-body communications include any communication of data or information via the body of the living subject 1002, i.e., communication via or associated with inter-body aspects, intra-body aspects, and a combination of the same. For example, inter-body aspects include communications associated with devices designed to attach to a body surface. Intra-body aspects include communications associated with data generated from within the body, e.g., by the body itself or by a device implanted, ingested, or otherwise locatable in, or partially in, the body. For example, intra-body communications are disclosed in the U.S. Provisional Patent Application No. 61/251,088, the entire content of which is hereby incorporated by reference.
Communications include and/or may be associated with software, hardware, circuitry, various devices, and combinations thereof.
The devices include devices associated with physiologic data generation, transmission, reception, communication. The devices further include various implantable, ingestible, insertable, and/or attachable devices associated with the human body or other living organisms. The devices still further include multimedia devices such as telephones, stereos, audio players, PDAs, handheld devices, and multimedia players.
The system for incorporating physiologic data enables exchange, transmission, receipt, manipulation, management, storage, and other activities and events related to physiologic data. Such activities and events may be contained within the system for incorporating physiologic data, partially integrated with the system for incorporating physiologic data, or associated with externalities, e.g., activities, systems, components, and the like which are external to the system for incorporating physiologic data.
The physiologic data environment includes any source of information or data, including remote computer systems, local computer devices. The information or data may comprise physiologic data in whole or in part, e.g., aggregated or generated with other types of data. The physiologic data may be pure or refined, e.g., physiologic data from which inferences are drawn.
As shown in
In one aspect, the external local node 1006 may be configured as a communication hub and may include any hardware device, software, and/or communications component(s), as well as systems, subsystems, and combinations of the same which generally function to communicate physiologic and non-physiologic data between the personal communicator 1004 and the external local node 1006. Communication of the data includes receiving, storing, manipulating, displaying, processing, and/or transmitting the data to the remote node 1010 via the network 1008.
In various aspects, the external local node 1006 also functions to communicate, e.g., receive and transmit, non-physiologic data. Example of non-physiologic data include gaming rules and data generated by a separate cardiac-related device such as an implanted pacemaker and communicated to the hub directly or indirectly, e.g., via the personal communicator 104.
Broad categories of external local nodes 1006 include, for example, base stations, personal communication devices, handheld devices, and mobile telephones. In various aspects, the external local node 1006 may be implemented as a handheld portable device, computer, mobile telephone, sometimes referred to as a smartphone, tablet personal computer (PC), kiosk, desktop computer, laptop computer, game console, or any combination thereof. Although some aspects of the external local node 1006 may be described with a mobile or fixed computing device implemented as a smart phone, personal digital assistant, laptop, desktop computer by way of example, it may be appreciated that the various aspects are not limited in this context. For example, a mobile computing device may comprise, or be implemented as, any type of wireless device, mobile station, or portable computing device with a self-contained power source, e.g., battery, such as the laptop computer, ultra-laptop computer, personal digital assistant (PDA), cellular telephone, combination cellular telephone/PDA, mobile unit, subscriber station, user terminal, portable computer, handheld computer, palmtop computer, wearable computer, media player, pager, messaging device, data communication device, and so forth. A fixed computing device, for example, may be implemented as a desk top computer, workstation, client/server computer, and so forth.
The external local node 1006 comprises personal communication devices including, for example, devices having communication and computer functionality and typically intended for individual use, e.g., mobile computers, sometimes referred to as “handheld devices.” Base stations comprise any device or appliance capable of receiving data such as physiologic data. Examples include computers, such as desktop computers and laptop computers, and intelligent devices/appliances. Intelligent devices/appliances include consumer and home devices and appliances that are capable of receipt of data such as physiologic data. Intelligent devices/appliances may also perform other data-related functions, e.g., transmit, display, store, and/or process data. Examples of intelligent devices/appliances include refrigerators, weight scales, toilets, televisions, door frame activity monitors, bedside monitors, bed scales. Such devices and appliances may include additional functionality such as sensing or monitoring various physiologic data, e.g., weight, heart rate. Mobile telephones include telephonic communication devices associated with various mobile technologies, e.g., cellular networks.
In various aspects, the external local node 1006 may provide voice and/or data communications functionality in accordance with different types of cellular radiotelephone systems. Examples of cellular radiotelephone systems may include Code Division Multiple Access (CDMA) systems, Global System for Mobile Communications (GSM) systems, North American Digital Cellular (NADC) systems, Time Division Multiple Access (TDMA) systems, Extended-TDMA (E-TDMA) systems, Narrowband Advanced Mobile Phone Service (NAMPS) systems, 3G systems such as Wide-band CDMA (WCDMA), CDMA-2000, Universal Mobile Telephone System (UMTS) systems, WiMAX (Worldwide Interoperability for Microwave Access, LTE (Long Term Evolution) and so forth.
In various embodiments, the external local node 1006 may be configured to provide voice and/or data communications functionality in accordance with different types of wireless network systems or protocols. Examples of suitable wireless network systems offering data communication services may include the Institute of Electrical and Electronics Engineers (IEEE) 802.xx series of protocols, such as the IEEE 802.1a/b/g/n series of standard protocols and variants (also referred to as “WiFi”), the IEEE 802.16 series of standard protocols and variants (also referred to as “WiMAX”), the IEEE 802.20 series of standard protocols and variants, and so forth. A mobile computing device may also utilize different types of shorter range wireless systems, such as a Bluetooth system operating in accordance with the Bluetooth Special Interest Group (SIG) series of protocols, including Bluetooth Specification versions v1.0, v1.1, v1.2, v1.0, v2.0 with Enhanced Data Rate (EDR), as well as one or more Bluetooth Profiles, and so forth. Other examples may include systems using infrared techniques or near-field communication techniques and protocols, such as electromagnetic induction (EMI) techniques.
In one aspect, the external local node 1006, for example, the hub, includes a software application associated with a mobile telephone of a patient. The application and mobile telephone function to receive physiologic data from a receiver, which, in turn, receives the physiologic data directly from an individual or indirectly, e.g., via a device. Examples of devices include cardiac devices and ingestible devices. The hub stores, manipulates, and/or forwards the data, alone or in combination with other data, via the network 1008 to a remote node 1010.
In various aspects, the external local node 1006 (hub) receives, generates, communicates, and/or transmits, physiologic data, alone or in combination with other data, i.e., non-physiologic data such as ingestion information from IEMs or various sources. Communication from the external local node 106 includes any transmission means or carriers, and combinations thereof, including wireless, wired, RF, conductive, etc. as is known in the art or as may become available in the future.
In various aspects, the handheld device includes software, e.g., a software agent/application, associated with the physiologic data. In various aspects of the handheld device, the software is preconfigured, i.e., configurable by the manufacturer/retailer; configurable by the consumer, i.e., downloadable from a website; or a combination of the same.
The base station includes systems, subsystems, devices, and/or components that receive, transmit, and/or relay the physiologic data. In various aspects, the base station communicably interoperates with a receiver such as the body-associated personal communicator 1004 and a communications network 1008 such as the Internet. Examples of base stations are computers, e.g., servers, personal computers, desktop computers, laptop computers, intelligent devices/appliances, etc., as heretofore discussed.
In various aspects, the base station may be embodied as an integrated unit or as distributed components, e.g., a desktop computer and a mobile telephone in communication with one another and in communication with a patch receiver and the Internet.
In various aspects, the base station includes the functionality to wirelessly receive and/or wirelessly transmit data, e.g., physiologic data received from and transmitted to the body-associated personal communicator 1004 and the Internet.
Further, in various aspects, the base station may incorporate and/or be associated with, e.g., communicate with, various devices. Such devices may generate, receive, and/or communicate data, e.g., physiologic data. The devices include, for example, “intelligent” devices such as gaming devices, e.g., electronic slot machines, handheld electronic games, electronic components associated with games and recreational activities.
The mobile telephone includes, for example, devices such as a short-range, portable electronic device used for mobile voice or data communication over a network of specialized cell site base stations. The mobile telephone is sometimes known as or referred to as “mobile,” “wireless,” “cellular phone,” “cell phone,” or “hand phone (HP).”
In addition to the standard voice function of a telephone, various aspects of mobile telephones may support many additional services and accessories such as short message service (SMS) for text messaging, email, packet switching for access to the Internet, Java gaming, wireless, e.g., short range data/voice communications, infrared, camera with video recorder, and multimedia messaging system (MMS) for sending and receiving photos and video. Some aspects of mobile telephones connect to a cellular network of base stations (cell sites), which is, in turn, interconnected to the public switched telephone network (PSTN) or satellite communications in the case of satellite phones. Various aspects of mobile telephones can connect to the Internet, at least a portion of which can be navigated using the mobile telephones.
In various aspects, the mobile telephone includes software, e.g., a software agent/application, associated with the physiologic data. One example is an auto refill application related to or integrated with an auto refill system to facilitate automated prescription refill functions. In various aspects of the mobile telephone, the software is preconfigured, i.e., configurable by the manufacturer/retailer; configurable by the consumer, i.e., downloadable from a website; or a combination of the same.
Further, various aspects of the hub include combinations of devices. One such combination is the body-associated personal communicator 1004 in communication with the handheld device or the mobile telephone. Thus, for example, the body-associated personal communicator 1004 wirelessly transmits physiologic data to the mobile telephone having a receiver and a software agent available thereon. The receiver of the mobile telephone receives the physiologic data. A software agent, e.g., an application, processes the physiologic data and displays various information related to the physiologic data via, for example, a customized graphical user interface (GUI). In various aspects, the software agent generates displays with a predetermined “look and feel,” i.e., recognizable to a user as belonging to a predetermined group of software programs, GUIs, source devices, communities, gaming software, etc.
More particularly, the personal communication system 1000 includes any environment having therein, or associated with, data or communication of physiologic data for a gaming or recreational purpose. Communication includes any method, act, or vehicle of communication, and/or combinations thereof. For example, communication methods include manual, wired, and wireless. Wireless technologies include radio signals, such as x-rays, ultraviolet light, the visible spectrum, infrared, microwaves, and radio waves, etc. Wireless services include voice and messaging, handheld and other Internet-enabled devices, data networking.
Vehicles of communication include the network 1008. In various aspects, the network 1008 comprises local area networks (LAN) as well as wide area networks (WAN) including without limitation Internet, wired channels, wireless channels, communication devices including telephones, computers, wire, radio, optical or other electromagnetic channels, and combinations thereof, including other devices and/or components capable of/associated with communicating data. For example, the communication environments include in-body communications, various devices, various modes of communications such as wireless communications, wired communications, and combinations of the same.
Wireless communication modes include any mode of communication between points that utilizes, at least in part, wireless technology including various protocols and combinations of protocols associated with wireless transmission, data, and devices. The points include, for example, wireless devices such as wireless headsets, audio and multimedia devices and equipment, such as audio players and multimedia players, telephones, including mobile telephones and cordless telephones, and computers and computer-related devices and components, such as printers.
Wired communication modes include any mode of communication between points that utilizes wired technology including various protocols and combinations of protocols associated with wired transmission, data, and devices. The points include, for example, devices such as audio and multimedia devices and equipment, such as audio players and multimedia players, telephones, including mobile telephones and cordless telephones, and computers and computer-related devices and components, such as printers.
In one aspect, the remote node 1010 comprises social network systems, commercial systems, healthcare systems, pharmacy systems, university systems, financial transaction systems, web communities, physician systems, family caregiver systems, regulatory agency systems, wholesaler/retailer systems as described in U.S. patent application Ser. No. 12/522,249 titled “INGESTIBLE EVENT MARKER DATA SYSTEM,” the disclosure of which is herein incorporated by reference in its entirety. In other aspects, the remote node 110 comprises state games, behavioral reflective games, psychological response games, synchronization games, actual progress games, and recreational games as described in PCT Patent Application No. PCT/US09/60713 dated Oct. 14, 2009 titled “METHOD AND SYSTEM FOR INCORPORATING PHYSIOLOGIC DATA IN A GAMING ENVIRONMENT” and published as WO 2010/045385, the disclosure of which is herein incorporated by reference in its entirety.
In various aspects, a computer system associated with the server 4040 or the server 4040 itself described in connection with
The processor may be configured to execute the operating logic. The processor may be any one of a number of single or multi-core processors known in the art. The storage may comprise volatile and non-volatile storage media configured to store persistent and temporal copies of the operating logic.
In various aspects, the operating logic may be configured to calculate a composite risk score as described hereinbelow. In various aspects, the operating logic may be implemented in instructions supported by the instruction set architecture (ISA) of the processor, or in higher level languages and compiled into the supported ISA. The operating logic may comprise on or more logic units or modules. The operating logic may be implemented in an object oriented manner. The operating logic may be configured to be executed in a multi-tasking and/or multi-threaded manner. In other embodiments, the operating logic may be implemented in hardware, such as a gate array.
In various aspects, the communication interface may be configured to facilitate communication between external systems or network-connected systems and the computing system. The communication may include transmission of the at least two distinct digitally watermarked copies and/or the pattern that represents a unique identifier. In various embodiments, the communication interface may be a wired or a wireless communication interface. An example of a wired communication interface may include, but is not limited to, a serial interface, a parallel interface, an Ethernet interface, or a Universal Serial Bus (USB) interface. An example of a wireless communication interface may include, but is not limited to, an interface implementing any variant of the 802.11 wireless protocol, an interface implementing a cellular network protocol, or a Bluetooth interface.
For various aspects, the processor may be packaged together with the operating logic. In various aspects, the processor may be packaged together with the operating logic to form a System in Package (SiP). In various embodiments, the processor may be integrated on the same die with the operating logic. In various embodiments, the processor may be packaged together with the operating logic to form a System on Chip (SoC).
Accordingly, a computer system associated with the server 4040 or the server 4040 itself described in connection with
In another aspect, the computer system may be configured to classify the subject 1002 into a predetermined risk group based on the composite risk score. The computer system also can be configured to dynamically reclassify the subject 1002 into a predetermined risk group based on the risk score.
In another aspect, the computer system may be configured to determine a circadian pattern from the contextual information received from the subject, calculate variability of the circadian pattern, and quantify the variability of the circadian pattern. The computer system also may be configured to determine a dominant circadian pattern, determine a deviation between the dominant circadian pattern and the circadian pattern, calculate a distribution of the deviations, and quantify the distribution of deviations by differential entropy. The computer system also may be configured to determine the dominant circadian pattern using principal component analysis. The computer system also may be configured to determine the composite risk score based at least in part on the variability of the circadian pattern.
In another aspect, the a computer system associated with the server 4040 or the server 4040 described in connection with
In another aspect, the computer system may be configured to calculate a composite risk score based on the quantified distribution of the daily variations. The computer system also may be configured to classify subjects 1002 into high risk or low risk classes based on the composite risk score. The computer system also can be implemented to temporarily classify subjects 1002 into high risk or low risk classes based on the composite risk score when the subjects' 1002 data temporarily increases in variability.
In another aspect, the a computer system associated with the server 4040 or the server 4040 described in connection with
In another aspect, the computer system may be configured to whiten the variation between the daily data and the dominant mode. The computer system also may be configured to determine how many whitened principal component analysis samples are above the predetermined threshold. The computer system may be configured to determine a variability score based how many samples of the daily data are above the predetermined threshold.
In another aspect, the a computer system associated with the server 4040 or the server 4040 described in connection with
The computer system also may be configured to determine a variability score based how many samples of the daily data are above the predetermined threshold. The computer system also may be configured to calculate a composite risk score based on the average deviation between the daily data and the weekly data. The computer system also may be configured to assess a risk associated with a subject based on the composite risk score.
The present invention may be defined by way of the following clauses. It will be understood that the features recited are interchangeable defined by the following clauses and their dependencies. That is, the features of the clauses may be combined to define the present invention.
Clauses
1. A computer-implemented method, comprising:
receiving, by a computer system, ingestible event marker (IEM) system information from a receiver worn by a subject, the IEM system information comprising physiological information and information associated with ingestion of medication by the subject, wherein the receiver is configured to communicate with the computer system;
receiving, by the computer system, contextual information associated with the subject; and
calculating, by the computer system, a composite risk score based on a combination of the IEM system information and the contextual information associated with the subject.
2. The computer-implemented method of Clause 1, comprising:
receiving, by the computer system, patient history information associated with the subject; and
calculating the composite risk score based on the patient history information.
3. The computer-implemented method of Clause 1 or Clause 2, comprising classifying the subject into a predetermined risk group based on the composite risk score.
4. The computer-implemented method of Clause 3, comprising dynamically reclassifying the subject into a predetermined risk group based on the risk score.
5. The computer-implemented method of any of Clauses 1 to 5, comprising:
determining, by the computer system, a circadian pattern from the contextual information received from the subject;
calculating, by the computer system, variability of the circadian pattern; and
quantifying, by the computer system, the variability of the circadian pattern.
6. The computer-implemented method of Clause 5, comprising:
determining, by the computer system, a dominant circadian pattern;
determining, by the computer system, a deviation between the dominant circadian pattern and the circadian pattern;
calculating, by the computer system, a distribution of the deviations; and
quantifying, by the computer system, the distribution of deviations by differential entropy.
7. The computer-implemented method of Clause 6, comprising, by the computer system, determining the dominant circadian pattern using principal component analysis.
8. The computer-implemented method of Clause 5, further comprising determining, by the computer system, the composite risk score based at least in part on the variability of the circadian pattern.
9. A computer-implemented method, comprising:
receiving, by a computer system, daily data from a subject;
calculating, by the computer system, the daily data into a dominant circadian pattern;
tracking, by the computer system, daily variations between the daily data and the dominant circadian pattern;
calculating, by the computer system, a distribution of the daily variations; and
quantifying, by the computer system, the distribution of the daily variations by differential entropy.
10. The computer-implemented method of Clause 9, comprising calculating, by the computer system, a composite risk score based on the quantified distribution of the daily variations.
11. The computer-implemented method of Clause 10, comprising classifying, by the computer system, subjects into high risk or low risk classes based on the composite risk score.
12. The computer-implemented method of Clause 10, comprising temporarily classifying, by the computer system, subjects into high risk or low risk classes based on the composite risk score when the subjects' data temporarily increases in variability.
13. A computer-implemented method, comprising:
receiving, by a computer system, daily data from a subject;
applying, by the computer system, principal component analysis to the received daily data to determine a dominant mode;
determining, by the computer system, a variation between the daily data and the dominant mode; and
determining, by the computer system, how many samples of the daily data are above a predetermined threshold.
14. The computer-implemented method of Clause 13, comprising, by the computer system, whitening the variation between the daily data and the dominant mode.
15. The computer-implemented method of Clause 14, comprising determining, by the computer system, how many whitened principal component analysis samples are above the predetermined threshold.
16. The computer-implemented method of Clause 13, comprising determining, by the computer system, a variability score based how many samples of the daily data are above the predetermined threshold.
17. A computer-implemented method, comprising:
receiving, by a computer system, daily data from a subject for at least one week;
extracting, by the computer system, at least one week of data from the received data;
whitening, by the computer, the at least one week of data; and
calculating, by the computer, an average deviation between the daily data and the weekly data.
18. The computer-implemented method of Clause 17, comprising determining, by the computer system, a variability score based how many samples of the daily data are above the predetermined threshold.
19. The computer-implemented method of Clause 17 or Clause 18, comprising calculating, by the computer system, a composite risk score based on the average deviation between the daily data and the weekly data.
20. The computer-implemented method of Clause 19, comprising assessing, by the computer system, a risk associated with a subject based on the composite risk score.
21. A system, comprising:
a computer system, comprising:
a processor; and
a memory coupled to the processor, wherein the memory stores program instructions, which when executed from the memory cause the processor to:
receive ingestible event marker (IEM) system information from a receiver worn by a subject, the IEM system information comprising physiological information and information associated with ingestion of medication by the subject, wherein the receiver is configured to communicate with the computer system;
receive contextual information associated with the subject; and
calculate a composite risk score based on a combination of the IEM system information and the contextual information associated with the subject.
22. The system of Clause 21, wherein the stored program instructions, when executed by the processor, cause the processor to:
receive patient history information associated with the subject; and
calculate the composite risk score based on the patient history information.
23. The system of Clause 21, wherein the stored program instructions, when executed by the processor, cause the processor to classify the subject into a predetermined risk group based on the composite risk score.
24. The system of Clause 23, wherein the stored program instructions, when executed by the processor, cause the processor to dynamically reclassify the subject into a predetermined risk group based on the risk score.
25. The system of Clause 21, wherein the stored program instructions, when executed by the processor, cause the processor to
determine a circadian pattern from the contextual information received from the subject;
calculate variability of the circadian pattern; and
quantify the variability of the circadian pattern.
26. The system of Clause 25, wherein the stored program instructions, when executed by the processor, cause the processor to:
determine a dominant circadian pattern;
determine a deviation between the dominant circadian pattern and the circadian pattern;
calculate a distribution of the deviations; and
quantify the distribution of deviations by differential entropy.
27. The system of Clause 26, wherein the stored program instructions, when executed by the processor, cause the processor to determine the dominant circadian pattern using principal component analysis.
28. The system of Clause 25, wherein the stored program instructions, when executed by the processor, cause the processor to determine the composite risk score based at least in part on the variability of the circadian pattern.
29. A system, comprising:
a computer system, comprising:
a processor; and
a memory coupled to the processor, wherein the memory stores program instructions, which when executed from the memory cause the processor to:
receive daily data from a subject;
calculate the daily data into a dominant circadian pattern;
track daily variations between the daily data and the dominant circadian pattern;
calculate a distribution of the daily variations; and
quantify the distribution of the daily variations by differential entropy.
30. The system of Clause 29, wherein the stored program instructions, when executed by the processor, cause the processor to calculate a composite risk score based on the quantified distribution of the daily variations.
31. The system of Clause 29 or Clause 30, wherein the stored program instructions, when executed by the processor, cause the processor to classify subjects into high risk or low risk classes based on the composite risk score.
32. The system of Clause 29 or Clause 30, wherein the stored program instructions, when executed by the processor, cause the processor to temporarily classify subjects into high risk or low risk classes based on the composite risk score when the subjects' data temporarily increases in variability.
33. A system, comprising:
a computer system, comprising:
a processor; and
receive daily data from a subject;
apply principal component analysis to the received daily data to determine a dominant mode;
determine a variation between the daily data and the dominant mode; and
determine how many samples of the daily data are above a predetermined threshold.
34. The system of Clause 33, wherein the stored program instructions, when executed by the processor, cause the processor to whiten the variation between the daily data and the dominant mode.
35. The system of Clause 34, wherein the stored program instructions, when executed by the processor, cause the processor to determine how many whitened principal component analysis samples are above the predetermined threshold.
36. The system of any of Clauses 33 to 35, wherein the stored program instructions, when executed by the processor, cause the processor to determine a variability score based how many samples of the daily data are above the predetermined threshold.
37. A system, comprising:
a computer system, comprising:
a processor; and
receive daily data from a subject for at least one week;
extract least one week of data from the received data;
whiten the at least one week of data; and
calculate an average deviation between the daily data and the weekly data.
38. The system of Clause 37, wherein the stored program instructions, when executed by the processor, cause the processor to determine a variability score based how many samples of the daily data are above the predetermined threshold.
39. The system of Clause 37 or Clause 38, wherein the stored program instructions, when executed by the processor, cause the processor to calculate a composite risk score based on the average deviation between the daily data and the weekly data.
40. The system of Clause 39, wherein the stored program instructions, when executed by the processor, cause the processor to assess a risk associated with a subject based on the composite risk score.
While various details have been set forth in the foregoing description, it will be appreciated that the various aspects of system, apparatus and methods for data collection and assessing outcomes may be practiced without these specific details. For example, for conciseness and clarity selected aspects have been shown in block diagram form rather than in detail. Some portions of the detailed descriptions provided herein may be presented in terms of instructions that operate on data that is stored in a computer memory. Such descriptions and representations are used by those skilled in the art to describe and convey the substance of their work to others skilled in the art. In general, an algorithm refers to a self-consistent sequence of steps leading to a desired result, where a “step” refers to a manipulation of physical quantities which may, though need not necessarily, take the form of electrical or magnetic signals capable of being stored, transferred, combined, compared, and otherwise manipulated. It is common usage to refer to these signals as bits, values, elements, symbols, characters, terms, numbers, or the like. These and similar terms may be associated with the appropriate physical quantities and are merely convenient labels applied to these quantities.
It is to be understood that this disclosure is not limited to particular aspects described, and as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.
Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present disclosure, representative illustrative methods and materials are now described.
All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference and are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present disclosure is not entitled to antedate such publication by virtue of prior disclosure. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.
Unless specifically stated otherwise as apparent from the foregoing discussion, it is appreciated that, throughout the foregoing description, discussions using terms such as “processing” or “computing” or “calculating” or “determining” or “displaying” or the like, refer to the action and processes of a computer system, or similar electronic computing device, that manipulates and transforms data represented as physical (electronic) quantities within the computer system's registers and memories into other data similarly represented as physical quantities within the computer system memories or registers or other such information storage, transmission or display devices.
It is worthy to note that any reference to “one aspect,” “an aspect,” “one aspect,” or “an aspect” means that a particular feature, structure, or characteristic described in connection with the aspect is included in at least one aspect. Thus, appearances of the phrases “in one aspect,” “in an aspect,” “in one aspect,” or “in an aspect” in various places throughout the specification are not necessarily all referring to the same aspect. Furthermore, the particular features, structures or characteristics may be combined in any suitable manner in one or more aspects.
Although various aspects have been described herein, many modifications, variations, substitutions, changes, and equivalents to those aspects may be implemented and will occur to those skilled in the art. Also, where materials are disclosed for certain components, other materials may be used. It is therefore to be understood that the foregoing description and the appended claims are intended to cover all such modifications and variations as falling within the scope of the disclosed aspects. The following claims are intended to cover all such modification and variations.
Some or all of the aspects described herein may generally comprise technologies for various aspects of content traceability using segmented watermark encoding, or otherwise according to technologies described herein. In a general sense, those skilled in the art will recognize that the various aspects described herein which can be implemented, individually and/or collectively, by a wide range of hardware, software, firmware, or any combination thereof can be viewed as being composed of various types of “electrical circuitry.” Consequently, as used herein “electrical circuitry” includes, but is not limited to, electrical circuitry having at least one discrete electrical circuit, electrical circuitry having at least one integrated circuit, electrical circuitry having at least one application specific integrated circuit, electrical circuitry forming a general purpose computing device configured by a computer program (e.g., a general purpose computer configured by a computer program which at least partially carries out processes and/or devices described herein, or a microprocessor configured by a computer program which at least partially carries out processes and/or devices described herein), electrical circuitry forming a memory device (e.g., forms of random access memory), and/or electrical circuitry forming a communications device (e.g., a modem, communications switch, or optical-electrical equipment). Those having skill in the art will recognize that the subject matter described herein may be implemented in an analog or digital fashion or some combination thereof.
The foregoing detailed description has set forth various aspects of the devices and/or processes via the use of block diagrams, flowcharts, and/or examples. Insofar as such block diagrams, flowcharts, and/or examples contain one or more functions and/or operations, it will be understood by those within the art that each function and/or operation within such block diagrams, flowcharts, or examples can be implemented, individually and/or collectively, by a wide range of hardware, software, firmware, or virtually any combination thereof. In one aspect, several portions of the subject matter described herein may be implemented via Application Specific Integrated Circuits (ASICs), Field Programmable Gate Arrays (FPGAs), digital signal processors (DSPs), or other integrated formats. Those skilled in the art will recognize, however, that some aspects of the aspects disclosed herein, in whole or in part, can be equivalently implemented in integrated circuits, as one or more computer programs running on one or more computers (e.g., as one or more programs running on one or more computer systems), as one or more programs running on one or more processors (e.g., as one or more programs running on one or more microprocessors), as firmware, or as virtually any combination thereof, and that designing the circuitry and/or writing the code for the software and or firmware would be well within the skill of one of skill in the art in light of this disclosure. In addition, those skilled in the art will appreciate that the mechanisms of the subject matter described herein are capable of being distributed as a program product in a variety of forms, and that an illustrative aspect of the subject matter described herein applies regardless of the particular type of signal bearing medium used to actually carry out the distribution. Examples of a signal bearing medium include, but are not limited to, the following: a recordable type medium such as a floppy disk, a hard disk drive, a Compact Disc (CD), a Digital Video Disk (DVD), a digital tape, a computer memory, etc.; and a transmission type medium such as a digital and/or an analog communication medium (e.g., a fiber optic cable, a waveguide, a wired communications link, a wireless communication link (e.g., transmitter, receiver, transmission logic, reception logic, etc.), etc.).
As will be apparent to those of skill in the art upon reading this disclosure, each of the individual aspects described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several aspects without departing from the scope of the present disclosure. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.
Although the foregoing disclosure has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this disclosure that certain changes and modifications may be made thereto without departing from the scope of the appended claims.
Accordingly, the preceding merely illustrates the principles of the disclosure. It will be appreciated that those skilled in the art will be able to devise various arrangements which, although not explicitly described or shown herein, embody the principles of the disclosure and are included within its scope. Furthermore, all examples and conditional language recited herein are principally intended to aid the reader in understanding the principles of the disclosure and the concepts contributed by the inventors to furthering the art, and are to be construed as being without limitation to such specifically recited examples and conditions. Moreover, all statements herein reciting principles, aspects, and aspects of the disclosure as well as specific examples thereof, are intended to encompass both structural and functional equivalents thereof. Additionally, it is intended that such equivalents include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. The scope of the present disclosure, therefore, is not intended to be limited to the example aspects shown and described herein. Rather, the scope of present disclosure is embodied by the appended claims.
Although various aspects have been described herein, many modifications, variations, substitutions, changes, and equivalents to those aspects may be implemented and will occur to those skilled in the art. Also, where materials are disclosed for certain components, other materials may be used. It is therefore to be understood that the foregoing description and the appended claims are intended to cover all such modifications and variations as falling within the scope of the disclosed aspects. The following claims are intended to cover all such modification and variations.
The present application is a U.S. national phase application filed under 35 U.S.C. § 371 of International Patent Application No. PCT/US2014/040570, entitled SYSTEM, APPARATUS AND METHODS FOR DATA COLLECTION AND ASSESSING OUTCOMES, filed Jun. 2, 2014, which application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 61/831,075 entitled SYSTEM, APPARATUS AND METHODS FOR DATA COLLECTION AND ASSESSING OUTCOMES, filed Jun. 4, 2013, the disclosures of which are herein incorporated by reference. This application is related to U.S. patent application Ser. No. 13/844,386, filed on Mar. 15, 2013, the disclosure of which application is herein incorporated by reference.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2014/040570 | 6/2/2014 | WO |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2014/197402 | 12/11/2014 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
3218638 | Honig | Nov 1965 | A |
3345989 | Reynolds | Oct 1967 | A |
3353539 | Preston | Nov 1967 | A |
3409721 | Applezweig | Nov 1968 | A |
3419736 | Walsh | Dec 1968 | A |
3589943 | Grubb et al. | Jun 1971 | A |
3607788 | Adolph | Sep 1971 | A |
3628669 | McKinnis et al. | Dec 1971 | A |
3642008 | Bolduc | Feb 1972 | A |
3679480 | Brown et al. | Jul 1972 | A |
3682160 | Murata | Aug 1972 | A |
3719183 | Schwartz | Mar 1973 | A |
3727616 | Lenzkes | Apr 1973 | A |
3799802 | Schneble, Jr. et al. | Mar 1974 | A |
3825016 | Lale et al. | Jul 1974 | A |
3828766 | Krasnow | Aug 1974 | A |
3837339 | Aisenberg et al. | Sep 1974 | A |
3893111 | Cotter | Jul 1975 | A |
3944064 | Bashaw et al. | Mar 1976 | A |
3967202 | Batz | Jun 1976 | A |
3989050 | Buchalter | Nov 1976 | A |
4017856 | Wiegand | Apr 1977 | A |
4055178 | Harrigan | Oct 1977 | A |
4062750 | Butler | Dec 1977 | A |
4077397 | Ellis | Mar 1978 | A |
4077398 | Ellis | Mar 1978 | A |
4082087 | Howson | Apr 1978 | A |
4090752 | Long | May 1978 | A |
4105023 | Merchese et al. | Aug 1978 | A |
4106348 | Auphan | Aug 1978 | A |
4129125 | Lester | Dec 1978 | A |
4133730 | DuBois et al. | Jan 1979 | A |
4141349 | Ory et al. | Feb 1979 | A |
4166453 | McClelland | Sep 1979 | A |
4239046 | Ong | Dec 1980 | A |
4251795 | Shibasaki et al. | Feb 1981 | A |
4269189 | Abraham | May 1981 | A |
4281664 | Duggan | Aug 1981 | A |
4331654 | Morris | May 1982 | A |
4345588 | Widder et al. | Aug 1982 | A |
4418697 | Tama | Dec 1983 | A |
4425117 | Hugemann | Jan 1984 | A |
4439196 | Higuchi | Mar 1984 | A |
4494950 | Fischell | Jan 1985 | A |
4526474 | Simon | Jul 1985 | A |
4547391 | Jenkins | Oct 1985 | A |
4559950 | Vaughan | Dec 1985 | A |
4564363 | Bagnall et al. | Jan 1986 | A |
4578061 | Lemelson | Mar 1986 | A |
4618533 | Steuck | Oct 1986 | A |
4635641 | Hoffman | Jan 1987 | A |
4654165 | Eisenber | Mar 1987 | A |
4663250 | Ong et al. | May 1987 | A |
4669479 | Dunseath | Jun 1987 | A |
4681111 | Silvian | Jul 1987 | A |
4687660 | Baker et al. | Aug 1987 | A |
4725997 | Urquhart et al. | Feb 1988 | A |
4749575 | Rotman et al. | Jun 1988 | A |
4763659 | Dunseath | Aug 1988 | A |
4767627 | Caldwell et al. | Aug 1988 | A |
4784162 | Ricks | Nov 1988 | A |
4793825 | Benjamin et al. | Dec 1988 | A |
4809705 | Ascher | Mar 1989 | A |
4835373 | Adams et al. | May 1989 | A |
4844076 | Lesho | Jul 1989 | A |
4871974 | Davis et al. | Oct 1989 | A |
4876093 | Theeuwes et al. | Oct 1989 | A |
4896261 | Nolan | Jan 1990 | A |
4975230 | Pinkhasov | Dec 1990 | A |
4987897 | Funke | Jan 1991 | A |
5000957 | Eckenhoff et al. | Mar 1991 | A |
5016634 | Vock et al. | May 1991 | A |
5079006 | Urquhart | Jan 1992 | A |
5167626 | Casper | Dec 1992 | A |
5176626 | Soehendra | Jan 1993 | A |
5179578 | Ishizu | Jan 1993 | A |
5245332 | Katzenstein et al. | Sep 1993 | A |
5261402 | DiSabito | Nov 1993 | A |
5263481 | Axelgaard et al. | Nov 1993 | A |
5276710 | Iwasaki | Jan 1994 | A |
5279607 | Schentag et al. | Jan 1994 | A |
5281287 | Lloyd | Jan 1994 | A |
5283136 | Peled et al. | Feb 1994 | A |
5288564 | Klein | Feb 1994 | A |
5305745 | Zacouto | Apr 1994 | A |
5318557 | Gross | Jun 1994 | A |
5394882 | Mawhinney | Mar 1995 | A |
5395366 | D'Andrea et al. | Mar 1995 | A |
5411535 | Fujii et al. | May 1995 | A |
5412372 | Parkhurst et al. | May 1995 | A |
5428961 | Sakakibara | Jul 1995 | A |
5436091 | Shackle et al. | Jul 1995 | A |
5443461 | Atkinson et al. | Aug 1995 | A |
5443843 | Curatolo et al. | Aug 1995 | A |
5458141 | Neil et al. | Oct 1995 | A |
5468222 | Altchuler | Nov 1995 | A |
5485841 | Watkin et al. | Jan 1996 | A |
5511548 | Riazzi et al. | Apr 1996 | A |
5538007 | Gorman | Jul 1996 | A |
5551953 | Lattin et al. | Sep 1996 | A |
5567210 | Bates et al. | Oct 1996 | A |
5596302 | Mastrocola et al. | Jan 1997 | A |
D377983 | Sabri et al. | Feb 1997 | S |
5600548 | Nguyen et al. | Feb 1997 | A |
5634466 | Gruner | Jun 1997 | A |
5634468 | Platt | Jun 1997 | A |
5638406 | Sogabe | Jun 1997 | A |
5645063 | Straka et al. | Jul 1997 | A |
5705189 | Lehmann et al. | Jan 1998 | A |
5720771 | Snell | Feb 1998 | A |
5738708 | Peachey et al. | Apr 1998 | A |
5740811 | Hedberg | Apr 1998 | A |
5757326 | Koyama et al. | May 1998 | A |
5792048 | Schaefer | Aug 1998 | A |
5802467 | Salazar | Sep 1998 | A |
5833716 | Bar-Or | Nov 1998 | A |
5836474 | Wessberg | Nov 1998 | A |
5845265 | Woolston | Dec 1998 | A |
5862803 | Besson | Jan 1999 | A |
5862808 | Albarello | Jan 1999 | A |
5868136 | Fox | Feb 1999 | A |
5914701 | Gersheneld et al. | Jun 1999 | A |
5917346 | Gord | Jun 1999 | A |
5921925 | Cartmell et al. | Jul 1999 | A |
5925030 | Gross et al. | Jul 1999 | A |
5925066 | Kroll et al. | Jul 1999 | A |
5957854 | Besson et al. | Sep 1999 | A |
5963132 | Yoakum et al. | Oct 1999 | A |
5965629 | Jung et al. | Oct 1999 | A |
5974124 | Schlueter, Jr. et al. | Oct 1999 | A |
5981166 | Mandecki | Nov 1999 | A |
5999846 | Pardey et al. | Dec 1999 | A |
6009350 | Renken | Dec 1999 | A |
6023631 | Cartmell et al. | Feb 2000 | A |
6038464 | Axelgaard et al. | Mar 2000 | A |
6042710 | Dubrow | Mar 2000 | A |
6047203 | Sackner | Apr 2000 | A |
6076016 | Feierbach et al. | Jun 2000 | A |
6081734 | Batz | Jun 2000 | A |
6083248 | Thompson | Jul 2000 | A |
6090489 | Hayakawa et al. | Jul 2000 | A |
6091975 | Daddona et al. | Jul 2000 | A |
6095985 | Raymond et al. | Aug 2000 | A |
6099482 | Brune et al. | Aug 2000 | A |
6115636 | Ryan | Sep 2000 | A |
6117077 | Del Mar et al. | Sep 2000 | A |
6122351 | Schlueter, Jr. et al. | Sep 2000 | A |
6141592 | Pauly | Oct 2000 | A |
6149940 | Maggi et al. | Nov 2000 | A |
6200265 | Walsh et al. | Mar 2001 | B1 |
6204764 | Maloney | Mar 2001 | B1 |
6206702 | Hayden et al. | Mar 2001 | B1 |
6217744 | Crosby | Apr 2001 | B1 |
6231593 | Meserol | May 2001 | B1 |
6245057 | Sieben et al. | Jun 2001 | B1 |
6269058 | Yamanoi et al. | Jul 2001 | B1 |
6275476 | Wood | Aug 2001 | B1 |
6285897 | Kilcoyne et al. | Sep 2001 | B1 |
6287252 | Lugo | Sep 2001 | B1 |
6288629 | Cofino et al. | Sep 2001 | B1 |
6289238 | Besson et al. | Sep 2001 | B1 |
6315719 | Rode et al. | Nov 2001 | B1 |
6342774 | Kreisinger et al. | Jan 2002 | B1 |
6344824 | Takasugi et al. | Feb 2002 | B1 |
6358202 | Arent | Mar 2002 | B1 |
6364834 | Reuss | Apr 2002 | B1 |
6366206 | Ishikawa et al. | Apr 2002 | B1 |
6368190 | Easter et al. | Apr 2002 | B1 |
6371927 | Brune | Apr 2002 | B1 |
6374670 | Spelman | Apr 2002 | B1 |
6380858 | Yarin et al. | Apr 2002 | B1 |
6390088 | Noehl et al. | May 2002 | B1 |
6394953 | Devlin et al. | May 2002 | B1 |
6394997 | Lemelson | May 2002 | B1 |
6409674 | Brockway et al. | Jun 2002 | B1 |
6411567 | Niemiec et al. | Jun 2002 | B1 |
6426863 | Munshi | Jul 2002 | B1 |
6432292 | Pinto et al. | Aug 2002 | B1 |
6440069 | Raymond et al. | Aug 2002 | B1 |
6441747 | Khair | Aug 2002 | B1 |
6453199 | Kobozev | Sep 2002 | B1 |
6477424 | Thompson et al. | Nov 2002 | B1 |
6482156 | Lliff | Nov 2002 | B2 |
6494829 | New et al. | Dec 2002 | B1 |
6496705 | Ng et al. | Dec 2002 | B1 |
6505077 | Kast et al. | Jan 2003 | B1 |
6525996 | Miyazawa | Feb 2003 | B1 |
6526315 | Inagawa | Feb 2003 | B1 |
6531026 | Takeichi et al. | Mar 2003 | B1 |
6540699 | Smith | Apr 2003 | B1 |
6544174 | West | Apr 2003 | B2 |
6564079 | Cory | May 2003 | B1 |
6572636 | Hagen et al. | Jun 2003 | B1 |
6574425 | Weiss et al. | Jun 2003 | B1 |
6577893 | Besson et al. | Jun 2003 | B1 |
6579231 | Phipps | Jun 2003 | B1 |
6595929 | Stivoric | Jul 2003 | B2 |
6599284 | Faour et al. | Jul 2003 | B2 |
6605038 | Teller | Aug 2003 | B1 |
6605046 | Del Mar | Aug 2003 | B1 |
6609018 | Cory | Aug 2003 | B2 |
6612984 | Kerr | Sep 2003 | B1 |
6632175 | Marshall | Oct 2003 | B1 |
6632216 | Houzego et al. | Oct 2003 | B2 |
6635279 | Kolter et al. | Oct 2003 | B2 |
6638231 | Govari et al. | Oct 2003 | B2 |
6643541 | Mok et al. | Nov 2003 | B2 |
6650718 | Fujimura et al. | Nov 2003 | B1 |
6654638 | Sweeney | Nov 2003 | B1 |
6663846 | McCombs | Dec 2003 | B1 |
6673474 | Yamamoto | Jan 2004 | B2 |
6679830 | Kolarovic et al. | Jan 2004 | B2 |
6680923 | Leon | Jan 2004 | B1 |
6683493 | Fujimora et al. | Jan 2004 | B1 |
6689117 | Sweeney et al. | Feb 2004 | B2 |
6694161 | Mehrotra | Feb 2004 | B2 |
6704602 | Berg et al. | Mar 2004 | B2 |
6720923 | Hayward et al. | Apr 2004 | B1 |
6738671 | Christophersom et al. | May 2004 | B2 |
6740033 | Olejniczak et al. | May 2004 | B1 |
6745082 | Axelgaard et al. | Jun 2004 | B2 |
6755783 | Cosentino | Jun 2004 | B2 |
6757523 | Fry | Jun 2004 | B2 |
6759968 | Zierolf | Jul 2004 | B2 |
6771174 | Broas | Aug 2004 | B2 |
6773429 | Sheppard et al. | Aug 2004 | B2 |
6800060 | Marshall | Oct 2004 | B2 |
6801137 | Eggers et al. | Oct 2004 | B2 |
6804558 | Haller et al. | Oct 2004 | B2 |
6814706 | Barton et al. | Nov 2004 | B2 |
6822554 | Vrijens et al. | Nov 2004 | B2 |
6836862 | Erekson et al. | Dec 2004 | B1 |
6839659 | Tarassenko et al. | Jan 2005 | B2 |
6840904 | Goldberg | Jan 2005 | B2 |
6842636 | Perrault | Jan 2005 | B2 |
6845272 | Thomsen | Jan 2005 | B1 |
6864780 | Doi | Mar 2005 | B2 |
6879810 | Bouet | Apr 2005 | B2 |
6882881 | Lesser et al. | Apr 2005 | B1 |
6897788 | Khair et al. | May 2005 | B2 |
6909878 | Haller | Jun 2005 | B2 |
6922592 | Thompson et al. | Jul 2005 | B2 |
6928370 | Anuzis et al. | Aug 2005 | B2 |
6929636 | Von Alten | Aug 2005 | B1 |
6937150 | Medema | Aug 2005 | B2 |
6939292 | Mizuno | Sep 2005 | B2 |
6942616 | Kerr | Sep 2005 | B2 |
6951536 | Yokoi | Oct 2005 | B2 |
6957107 | Rogers et al. | Oct 2005 | B2 |
6959929 | Pugnet et al. | Nov 2005 | B2 |
6968153 | Heinonen | Nov 2005 | B1 |
6987965 | Ng et al. | Jan 2006 | B2 |
6990082 | Zehavi et al. | Jan 2006 | B1 |
7002476 | Rapchak | Feb 2006 | B2 |
7004395 | Koenck | Feb 2006 | B2 |
7009634 | Iddan et al. | Mar 2006 | B2 |
7009946 | Kardach | Mar 2006 | B1 |
7013162 | Gorsuch | Mar 2006 | B2 |
7016648 | Haller | Mar 2006 | B2 |
7020508 | Stivoric | Mar 2006 | B2 |
7023940 | Nakamura et al. | Apr 2006 | B2 |
7024248 | Penner et al. | Apr 2006 | B2 |
7031745 | Shen | Apr 2006 | B2 |
7031857 | Tarassenko et al. | Apr 2006 | B2 |
7039453 | Mullick | May 2006 | B2 |
7044911 | Drinan et al. | May 2006 | B2 |
7046649 | Awater et al. | May 2006 | B2 |
7050419 | Azenkot et al. | May 2006 | B2 |
7062308 | Jackson | Jun 2006 | B1 |
7069062 | Minotani et al. | Jun 2006 | B2 |
7076437 | Levy | Jul 2006 | B1 |
7081693 | Hamel et al. | Jul 2006 | B2 |
7091726 | Sano et al. | Aug 2006 | B2 |
7118531 | Krill | Oct 2006 | B2 |
7125382 | Zhou et al. | Oct 2006 | B2 |
7127300 | Mazar et al. | Oct 2006 | B2 |
7146228 | Nielsen | Dec 2006 | B2 |
7146449 | Do et al. | Dec 2006 | B2 |
7149581 | Goedeke et al. | Dec 2006 | B2 |
7154071 | Sattler et al. | Dec 2006 | B2 |
7155232 | Godfrey et al. | Dec 2006 | B2 |
7160258 | Imran | Jan 2007 | B2 |
7161484 | Tsoukalis | Jan 2007 | B2 |
7164942 | Avrahami | Jan 2007 | B2 |
7171166 | Ng et al. | Jan 2007 | B2 |
7171177 | Park et al. | Jan 2007 | B2 |
7171259 | Rytky | Jan 2007 | B2 |
7176784 | Gilbert et al. | Feb 2007 | B2 |
7187960 | Abreu | Mar 2007 | B2 |
7188767 | Penuela | Mar 2007 | B2 |
7194038 | Inkinen | Mar 2007 | B1 |
7206630 | Tarler | Apr 2007 | B1 |
7209790 | Thompson et al. | Apr 2007 | B2 |
7215660 | Perlman | May 2007 | B2 |
7215991 | Besson | May 2007 | B2 |
7218967 | Bergelson | May 2007 | B2 |
7231451 | Law | Jun 2007 | B2 |
7243118 | Lou | Jul 2007 | B2 |
7246521 | Kim | Jul 2007 | B2 |
7249212 | Do | Jul 2007 | B2 |
7252792 | Perrault | Aug 2007 | B2 |
7253716 | Lovoi et al. | Aug 2007 | B2 |
7261690 | Teller | Aug 2007 | B2 |
7270633 | Goscha | Sep 2007 | B1 |
7273454 | Raymond et al. | Sep 2007 | B2 |
7285090 | Stivoric et al. | Oct 2007 | B2 |
7289855 | Nghiem | Oct 2007 | B2 |
7291014 | Chung et al. | Nov 2007 | B2 |
7291497 | Holmes | Nov 2007 | B2 |
7292139 | Mazar et al. | Nov 2007 | B2 |
7294105 | Islam | Nov 2007 | B1 |
7295877 | Govari | Nov 2007 | B2 |
7311665 | Hawthorne | Dec 2007 | B2 |
7313163 | Liu | Dec 2007 | B2 |
7317378 | Jarvis et al. | Jan 2008 | B2 |
7318808 | Tarassenko et al. | Jan 2008 | B2 |
7336732 | Wiss | Feb 2008 | B1 |
7336929 | Yasuda | Feb 2008 | B2 |
7342895 | Serpa | Mar 2008 | B2 |
7346380 | Axelgaard et al. | Mar 2008 | B2 |
7349722 | Witkowski et al. | Mar 2008 | B2 |
7352998 | Palin | Apr 2008 | B2 |
7353258 | Washburn | Apr 2008 | B2 |
7357891 | Yang et al. | Apr 2008 | B2 |
7359674 | Markki | Apr 2008 | B2 |
7366558 | Virtanen et al. | Apr 2008 | B2 |
7366675 | Walker et al. | Apr 2008 | B1 |
7368190 | Heller et al. | May 2008 | B2 |
7368191 | Andelman et al. | May 2008 | B2 |
7373196 | Ryu et al. | May 2008 | B2 |
7375739 | Robbins | May 2008 | B2 |
7376435 | McGowan | May 2008 | B2 |
7382247 | Welch et al. | Jun 2008 | B2 |
7382263 | Danowski et al. | Jun 2008 | B2 |
7387607 | Holt | Jun 2008 | B2 |
7388903 | Godfrey et al. | Jun 2008 | B2 |
7389088 | Kim | Jun 2008 | B2 |
7392015 | Farlow | Jun 2008 | B1 |
7395106 | Ryu et al. | Jul 2008 | B2 |
7396330 | Banet | Jul 2008 | B2 |
7404968 | Abrams et al. | Jul 2008 | B2 |
7413544 | Kerr | Aug 2008 | B2 |
7414534 | Kroll et al. | Aug 2008 | B1 |
7414543 | Rye et al. | Aug 2008 | B2 |
7415242 | Ngan | Aug 2008 | B1 |
7419468 | Shimizu et al. | Sep 2008 | B2 |
7424268 | Diener | Sep 2008 | B2 |
7424319 | Muehlsteff | Sep 2008 | B2 |
7427266 | Ayer et al. | Sep 2008 | B2 |
7433731 | Matsumura et al. | Oct 2008 | B2 |
7449262 | Christie et al. | Nov 2008 | B2 |
7462150 | Bharmi | Dec 2008 | B1 |
7471665 | Perlman | Dec 2008 | B2 |
7485093 | Glukhovsky | Feb 2009 | B2 |
7485095 | Shusterman | Feb 2009 | B2 |
7499674 | Salokannel | Mar 2009 | B2 |
7502643 | Farringdon et al. | Mar 2009 | B2 |
7505795 | Lim et al. | Mar 2009 | B1 |
7508248 | Yoshida | Mar 2009 | B2 |
7510121 | Koenck | Mar 2009 | B2 |
7512448 | Malick | Mar 2009 | B2 |
7512860 | Miyazaki et al. | Mar 2009 | B2 |
7515043 | Welch | Apr 2009 | B2 |
7519416 | Sula et al. | Apr 2009 | B2 |
7523756 | Minai | Apr 2009 | B2 |
7525426 | Edelstein | Apr 2009 | B2 |
7527807 | Choi et al. | May 2009 | B2 |
7539533 | Tran | May 2009 | B2 |
7542878 | Nanikashvili | Jun 2009 | B2 |
7547278 | Miyazaki et al. | Jun 2009 | B2 |
7551590 | Haller | Jun 2009 | B2 |
7554452 | Cole | Jun 2009 | B2 |
7558620 | Ishibashi | Jul 2009 | B2 |
7558622 | Tran | Jul 2009 | B2 |
7558965 | Wheeler et al. | Jul 2009 | B2 |
7575005 | Mumford | Aug 2009 | B2 |
7614743 | Geiger | Nov 2009 | B2 |
7616111 | Covannon | Nov 2009 | B2 |
7616710 | Kim et al. | Nov 2009 | B2 |
7617001 | Penner et al. | Nov 2009 | B2 |
7639473 | Hsu et al. | Dec 2009 | B2 |
7640802 | King et al. | Jan 2010 | B2 |
7647112 | Tracey | Jan 2010 | B2 |
7647185 | Tarassenko et al. | Jan 2010 | B2 |
7653031 | Godfrey et al. | Jan 2010 | B2 |
7668437 | Yamada et al. | Feb 2010 | B1 |
7683761 | Burghard et al. | Feb 2010 | B2 |
7672703 | Yeo et al. | Mar 2010 | B2 |
7672714 | Kuo | Mar 2010 | B2 |
7673679 | Harrison et al. | Mar 2010 | B2 |
7678043 | Gilad | Mar 2010 | B2 |
7689437 | Teller et al. | Mar 2010 | B1 |
7689833 | Lange | Mar 2010 | B2 |
7697994 | VanDanacker et al. | Apr 2010 | B2 |
7712288 | Ramasubramanian et al. | May 2010 | B2 |
7720036 | Sadri | May 2010 | B2 |
7729776 | Von Arx et al. | Jun 2010 | B2 |
7733224 | Tran | Jun 2010 | B2 |
7736318 | Costentino | Jun 2010 | B2 |
7747454 | Bartfeld et al. | Jun 2010 | B2 |
7756587 | Penner et al. | Jul 2010 | B2 |
7764996 | Zhang et al. | Jul 2010 | B2 |
7779614 | McGonagle et al. | Aug 2010 | B1 |
7796043 | Euliano et al. | Sep 2010 | B2 |
7797033 | D'Andrea et al. | Sep 2010 | B2 |
7806852 | Jursen | Oct 2010 | B1 |
7809399 | Lu | Oct 2010 | B2 |
7811231 | Jin et al. | Oct 2010 | B2 |
7844341 | Von Arx et al. | Nov 2010 | B2 |
7857766 | Lasater et al. | Dec 2010 | B2 |
7860731 | Jackson et al. | Dec 2010 | B2 |
7871734 | Hertz et al. | Jan 2011 | B2 |
7899526 | Benditt et al. | Mar 2011 | B2 |
7904133 | Gehman et al. | Mar 2011 | B2 |
D639437 | Bishay et al. | Jun 2011 | S |
7978064 | Zdeblick et al. | Jul 2011 | B2 |
8025149 | Sterry et al. | Sep 2011 | B2 |
8036731 | Kimchy et al. | Oct 2011 | B2 |
8036748 | Zdeblick et al. | Oct 2011 | B2 |
8055334 | Savage et al. | Nov 2011 | B2 |
8060249 | Bear et al. | Nov 2011 | B2 |
8073707 | Teller et al. | Dec 2011 | B2 |
8083128 | Dembo et al. | Dec 2011 | B2 |
8123576 | Kim | Feb 2012 | B2 |
8135596 | Jung et al. | Mar 2012 | B2 |
8142513 | Shalon et al. | Mar 2012 | B2 |
8177611 | Kang | May 2012 | B2 |
8180425 | Selvitelli et al. | May 2012 | B2 |
8185191 | Shapiro et al. | May 2012 | B1 |
8185646 | Headley | May 2012 | B2 |
8200320 | Kovacs | Jun 2012 | B2 |
8209018 | Osorio et al. | Jun 2012 | B2 |
8214007 | Baker et al. | Jul 2012 | B2 |
8224667 | Miller et al. | Jul 2012 | B1 |
8238998 | Park | Aug 2012 | B2 |
8249686 | Libbus et al. | Aug 2012 | B2 |
8253586 | Matak | Aug 2012 | B1 |
8254853 | Rofougaran | Aug 2012 | B2 |
8258962 | Robertson et al. | Sep 2012 | B2 |
8262394 | Walker et al. | Sep 2012 | B2 |
8271106 | Wehba et al. | Sep 2012 | B2 |
8285356 | Bly et al. | Oct 2012 | B2 |
8290574 | Felid et al. | Oct 2012 | B2 |
8301232 | Albert et al. | Oct 2012 | B2 |
8308640 | Baldus et al. | Nov 2012 | B2 |
8314619 | Takiguchi | Nov 2012 | B2 |
8315687 | Cross et al. | Nov 2012 | B2 |
8343068 | Najafi et al. | Jan 2013 | B2 |
8369936 | Farringdon et al. | Feb 2013 | B2 |
8386009 | Lindberg et al. | Feb 2013 | B2 |
8389003 | Mintchev et al. | Mar 2013 | B2 |
8404275 | Habboushe | Mar 2013 | B2 |
8440274 | Wang | May 2013 | B2 |
8454528 | Yuen et al. | Jun 2013 | B2 |
8454561 | Uber, III et al. | Jun 2013 | B2 |
8514086 | Harper et al. | Aug 2013 | B2 |
8542123 | Robertson | Sep 2013 | B2 |
8564432 | Covannon et al. | Oct 2013 | B2 |
8564627 | Suzuki et al. | Oct 2013 | B2 |
8583227 | Savage et al. | Nov 2013 | B2 |
8597186 | Hafezi et al. | Dec 2013 | B2 |
8634838 | Hellwig et al. | Jan 2014 | B2 |
8660645 | Stevenson et al. | Feb 2014 | B2 |
8668280 | Heller et al. | Mar 2014 | B2 |
8668643 | Kinast | Mar 2014 | B2 |
8718193 | Arne et al. | May 2014 | B2 |
8722085 | McKinney et al. | May 2014 | B2 |
8762733 | Derchak et al. | Jun 2014 | B2 |
8771183 | Sloan | Jul 2014 | B2 |
8810260 | Zhou | Aug 2014 | B1 |
8810409 | Robertson et al. | Aug 2014 | B2 |
8823510 | Downey et al. | Sep 2014 | B2 |
8836513 | Hafezi et al. | Sep 2014 | B2 |
8838217 | Myr | Sep 2014 | B2 |
8858432 | Robertson | Oct 2014 | B2 |
8868453 | Zdeblick | Oct 2014 | B2 |
8908943 | Berry et al. | Dec 2014 | B2 |
8926509 | Magar et al. | Jan 2015 | B2 |
8932221 | Colliou et al. | Jan 2015 | B2 |
8945005 | Hafezi et al. | Feb 2015 | B2 |
8956287 | Zdeblick et al. | Feb 2015 | B2 |
8966973 | Milone | Mar 2015 | B1 |
8989837 | Weinstein et al. | Mar 2015 | B2 |
9031658 | Chiao et al. | May 2015 | B2 |
9047746 | Euliano et al. | Jun 2015 | B1 |
9060708 | Robertson et al. | Jun 2015 | B2 |
9083589 | Arne et al. | Jul 2015 | B2 |
9088168 | Mach et al. | Jul 2015 | B2 |
9125868 | McKinney et al. | Sep 2015 | B2 |
9189941 | Eschelman et al. | Nov 2015 | B2 |
9198608 | Hafezi et al. | Dec 2015 | B2 |
9226663 | Fei | Jan 2016 | B2 |
9226679 | Balda | Jan 2016 | B2 |
9235683 | Robertson et al. | Jan 2016 | B2 |
9270025 | Robertson et al. | Feb 2016 | B2 |
9277864 | Yang et al. | Mar 2016 | B2 |
9278177 | Edwards et al. | Mar 2016 | B2 |
9320455 | Hafezi et al. | Apr 2016 | B2 |
9433371 | Hafezi et al. | Sep 2016 | B2 |
9439582 | Berkman et al. | Sep 2016 | B2 |
9439599 | Thompson et al. | Sep 2016 | B2 |
9517012 | Lane et al. | Dec 2016 | B2 |
9603550 | Behzadi | Mar 2017 | B2 |
9756874 | Arne et al. | Sep 2017 | B2 |
9883819 | Jensen et al. | Feb 2018 | B2 |
10772522 | Zadig | Sep 2020 | B2 |
20010027331 | Thompson | Oct 2001 | A1 |
20010031071 | Nichols et al. | Oct 2001 | A1 |
20010039503 | Chan et al. | Nov 2001 | A1 |
20010044588 | Mault | Nov 2001 | A1 |
20010051766 | Gazdinski | Dec 2001 | A1 |
20010056262 | Cabiri et al. | Dec 2001 | A1 |
20020002326 | Causey et al. | Jan 2002 | A1 |
20020019586 | Teller et al. | Feb 2002 | A1 |
20020026111 | Ackerman | Feb 2002 | A1 |
20020032384 | Raymond et al. | Mar 2002 | A1 |
20020032385 | Raymond et al. | Mar 2002 | A1 |
20020040278 | Anuzis et al. | Apr 2002 | A1 |
20020067270 | Yarin et al. | Jun 2002 | A1 |
20020077620 | Sweeney et al. | Jun 2002 | A1 |
20020128934 | Shaer | Sep 2002 | A1 |
20020132226 | Nair | Sep 2002 | A1 |
20020138009 | Brockway et al. | Sep 2002 | A1 |
20020184415 | Naghavi et al. | Dec 2002 | A1 |
20020192159 | Reitberg | Dec 2002 | A1 |
20020193669 | Glukhovsky | Dec 2002 | A1 |
20020193846 | Pool et al. | Dec 2002 | A1 |
20020198470 | Imran et al. | Dec 2002 | A1 |
20030017826 | Fishman | Jan 2003 | A1 |
20030023150 | Yokoi et al. | Jan 2003 | A1 |
20030028226 | Thompson | Feb 2003 | A1 |
20030037063 | Schwartz | Feb 2003 | A1 |
20030063522 | Sagar | Apr 2003 | A1 |
20030065536 | Hansen | Apr 2003 | A1 |
20030076179 | Branch et al. | Apr 2003 | A1 |
20030083559 | Thompson | May 2003 | A1 |
20030126593 | Mault | Jul 2003 | A1 |
20030130714 | Nielsen et al. | Jul 2003 | A1 |
20030135128 | Suffin et al. | Jul 2003 | A1 |
20030135392 | Vrijens et al. | Jul 2003 | A1 |
20030152622 | Louie-Helm et al. | Aug 2003 | A1 |
20030158466 | Lynn et al. | Aug 2003 | A1 |
20030158756 | Abramson | Aug 2003 | A1 |
20030162556 | Libes | Aug 2003 | A1 |
20030164401 | Andreasson et al. | Sep 2003 | A1 |
20030167000 | Mullick et al. | Sep 2003 | A1 |
20030171791 | KenKnight | Sep 2003 | A1 |
20030171898 | Tarassenko et al. | Sep 2003 | A1 |
20030181788 | Yokoi et al. | Sep 2003 | A1 |
20030181815 | Ebner et al. | Sep 2003 | A1 |
20030185286 | Yuen | Oct 2003 | A1 |
20030187337 | Tarassenko et al. | Oct 2003 | A1 |
20030187338 | Say et al. | Oct 2003 | A1 |
20030195403 | Berner et al. | Oct 2003 | A1 |
20030198619 | Dong et al. | Oct 2003 | A1 |
20030213495 | Fujita et al. | Nov 2003 | A1 |
20030214579 | Iddan | Nov 2003 | A1 |
20030216622 | Meron et al. | Nov 2003 | A1 |
20030216625 | Phipps | Nov 2003 | A1 |
20030216666 | Ericson et al. | Nov 2003 | A1 |
20030216729 | Marchitto | Nov 2003 | A1 |
20030216793 | Karlsson et al. | Nov 2003 | A1 |
20030229382 | Sun et al. | Dec 2003 | A1 |
20030232895 | Omidian et al. | Dec 2003 | A1 |
20040008123 | Carrender et al. | Jan 2004 | A1 |
20040018476 | LaDue | Jan 2004 | A1 |
20040019172 | Yang et al. | Jan 2004 | A1 |
20040034295 | Salganicoff | Feb 2004 | A1 |
20040049245 | Gass | Mar 2004 | A1 |
20040073095 | Causey et al. | Apr 2004 | A1 |
20040073454 | Urquhart et al. | Apr 2004 | A1 |
20040077995 | Ferek-Petric | Apr 2004 | A1 |
20040082982 | Gord et al. | Apr 2004 | A1 |
20040087839 | Raymond et al. | May 2004 | A1 |
20040092801 | Drakulic | May 2004 | A1 |
20040106859 | Say et al. | Jun 2004 | A1 |
20040111011 | Uchiyama et al. | Jun 2004 | A1 |
20040115507 | Potter et al. | Jun 2004 | A1 |
20040115517 | Fukada et al. | Jun 2004 | A1 |
20040121015 | Chidlaw et al. | Jun 2004 | A1 |
20040122296 | Hatlestad | Jun 2004 | A1 |
20040122297 | Stahmann et al. | Jun 2004 | A1 |
20040138558 | Dunki-Jacobs et al. | Jul 2004 | A1 |
20040147326 | Stiles | Jul 2004 | A1 |
20040148140 | Tarassenko et al. | Jul 2004 | A1 |
20040153007 | Harris | Aug 2004 | A1 |
20040167226 | Serafini | Aug 2004 | A1 |
20040167801 | Say et al. | Aug 2004 | A1 |
20040171914 | Avni | Sep 2004 | A1 |
20040193020 | Chiba | Sep 2004 | A1 |
20040193029 | Glukhovsky | Sep 2004 | A1 |
20040193446 | Mayer et al. | Sep 2004 | A1 |
20040199222 | Sun et al. | Oct 2004 | A1 |
20040215084 | Shimizu et al. | Oct 2004 | A1 |
20040218683 | Batra | Nov 2004 | A1 |
20040220643 | Schmidt | Nov 2004 | A1 |
20040224644 | Wu | Nov 2004 | A1 |
20040225199 | Evanyk | Nov 2004 | A1 |
20040253304 | Gross et al. | Dec 2004 | A1 |
20040258571 | Lee et al. | Dec 2004 | A1 |
20040259899 | Sanghvi et al. | Dec 2004 | A1 |
20040260154 | Sidelnik | Dec 2004 | A1 |
20040267240 | Gross et al. | Dec 2004 | A1 |
20050017841 | Doi | Jan 2005 | A1 |
20050020887 | Goldberg | Jan 2005 | A1 |
20050021103 | DiLorenzo | Jan 2005 | A1 |
20050021370 | Riff | Jan 2005 | A1 |
20050021372 | Mikkelsen | Jan 2005 | A1 |
20050024198 | Ward | Feb 2005 | A1 |
20050027175 | Yang | Feb 2005 | A1 |
20050027205 | Tarassenko et al. | Feb 2005 | A1 |
20050038321 | Fujita et al. | Feb 2005 | A1 |
20050038680 | McMahon | Feb 2005 | A1 |
20050043583 | Killman et al. | Feb 2005 | A1 |
20050043634 | Yokoi et al. | Feb 2005 | A1 |
20050043894 | Fernandez | Feb 2005 | A1 |
20050054897 | Hashimoto et al. | Mar 2005 | A1 |
20050055014 | Coppeta et al. | Mar 2005 | A1 |
20050062644 | Leci | Mar 2005 | A1 |
20050065407 | Nakamura et al. | Mar 2005 | A1 |
20050070778 | Lackey | Mar 2005 | A1 |
20050075145 | Dvorak et al. | Apr 2005 | A1 |
20050090753 | Goor et al. | Apr 2005 | A1 |
20050092108 | Andermo | May 2005 | A1 |
20050096514 | Starkebaum | May 2005 | A1 |
20050096562 | Delalic et al. | May 2005 | A1 |
20050101843 | Quinn | May 2005 | A1 |
20050101872 | Sattler | May 2005 | A1 |
20050115561 | Stahmann et al. | Jun 2005 | A1 |
20050116820 | Goldreich | Jun 2005 | A1 |
20050117389 | Worledge | Jun 2005 | A1 |
20050121322 | Say et al. | Jun 2005 | A1 |
20050131281 | Ayer et al. | Jun 2005 | A1 |
20050137480 | Alt et al. | Jun 2005 | A1 |
20050143623 | Kojima | Jun 2005 | A1 |
20050146594 | Nakatani et al. | Jul 2005 | A1 |
20050148883 | Boesen | Jul 2005 | A1 |
20050151625 | Lai | Jul 2005 | A1 |
20050154277 | Tang et al. | Jul 2005 | A1 |
20050154428 | Bruinsma | Jul 2005 | A1 |
20050156709 | Gilbert et al. | Jul 2005 | A1 |
20050159789 | Brockway | Jul 2005 | A1 |
20050165323 | Montgomery | Jul 2005 | A1 |
20050177069 | Takizawa | Aug 2005 | A1 |
20050182389 | LaPorte | Aug 2005 | A1 |
20050187789 | Hatlestad et al. | Aug 2005 | A1 |
20050192489 | Marshall | Sep 2005 | A1 |
20050197680 | DelMain et al. | Sep 2005 | A1 |
20050228268 | Cole | Oct 2005 | A1 |
20050234307 | Heinonen | Oct 2005 | A1 |
20050240305 | Bogash et al. | Oct 2005 | A1 |
20050245794 | Dinsmoor | Nov 2005 | A1 |
20050245839 | Stivoric et al. | Nov 2005 | A1 |
20050259768 | Yang et al. | Nov 2005 | A1 |
20050261559 | Mumford | Nov 2005 | A1 |
20050267550 | Hess et al. | Dec 2005 | A1 |
20050267556 | Shuros et al. | Dec 2005 | A1 |
20050267756 | Schultz et al. | Dec 2005 | A1 |
20050277912 | John | Dec 2005 | A1 |
20050277999 | Strother et al. | Dec 2005 | A1 |
20050280539 | Pettus | Dec 2005 | A1 |
20050285732 | Sengupta et al. | Dec 2005 | A1 |
20050285746 | Sengupta | Dec 2005 | A1 |
20050288594 | Lewkowicz et al. | Dec 2005 | A1 |
20060001496 | Abrosimov et al. | Jan 2006 | A1 |
20060028727 | Moon et al. | Feb 2006 | A1 |
20060036134 | Tarassenko et al. | Feb 2006 | A1 |
20060058602 | Kwiatkowski et al. | Mar 2006 | A1 |
20060061472 | Lovoi et al. | Mar 2006 | A1 |
20060065713 | Kingery | Mar 2006 | A1 |
20060068006 | Begleiter | Mar 2006 | A1 |
20060074283 | Henderson | Apr 2006 | A1 |
20060074319 | Barnes et al. | Apr 2006 | A1 |
20060078765 | Yang et al. | Apr 2006 | A1 |
20060089858 | Ling | Apr 2006 | A1 |
20060095091 | Drew | May 2006 | A1 |
20060095093 | Bettesh et al. | May 2006 | A1 |
20060100533 | Han | May 2006 | A1 |
20060109058 | Keating | May 2006 | A1 |
20060110962 | Powell | May 2006 | A1 |
20060122474 | Teller et al. | Jun 2006 | A1 |
20060122525 | Shusterman | Jun 2006 | A1 |
20060122667 | Chavan et al. | Jun 2006 | A1 |
20060129060 | Lee et al. | Jun 2006 | A1 |
20060136266 | Tarassenko et al. | Jun 2006 | A1 |
20060142648 | Banet | Jun 2006 | A1 |
20060145876 | Kimura | Jul 2006 | A1 |
20060148254 | McLean | Jul 2006 | A1 |
20060149339 | Burnes | Jul 2006 | A1 |
20060155174 | Glukhovsky et al. | Jul 2006 | A1 |
20060155183 | Kroecker | Jul 2006 | A1 |
20060158820 | Takiguchi | Jul 2006 | A1 |
20060161225 | Sormann et al. | Jul 2006 | A1 |
20060179949 | Kim | Aug 2006 | A1 |
20060183992 | Kawashima | Aug 2006 | A1 |
20060183993 | Horn | Aug 2006 | A1 |
20060184092 | Atanasoska et al. | Aug 2006 | A1 |
20060204738 | Dubrow et al. | Sep 2006 | A1 |
20060204764 | Hirao et al. | Sep 2006 | A1 |
20060210626 | Spaeder | Sep 2006 | A1 |
20060216603 | Choi | Sep 2006 | A1 |
20060218011 | Walker | Sep 2006 | A1 |
20060229053 | Sivard | Oct 2006 | A1 |
20060235489 | Drew | Oct 2006 | A1 |
20060243288 | Kim et al. | Nov 2006 | A1 |
20060247505 | Siddiqui | Nov 2006 | A1 |
20060253004 | Frisch et al. | Nov 2006 | A1 |
20060253005 | Drinan | Nov 2006 | A1 |
20060255064 | Donaldson | Nov 2006 | A1 |
20060265246 | Hoag | Nov 2006 | A1 |
20060267774 | Feinberg et al. | Nov 2006 | A1 |
20060270346 | Ibrahim | Nov 2006 | A1 |
20060273882 | Posamentier | Dec 2006 | A1 |
20060276702 | McGinnis | Dec 2006 | A1 |
20060280227 | Pinkney | Dec 2006 | A1 |
20060282001 | Noel | Dec 2006 | A1 |
20060285607 | Strodtbeck et al. | Dec 2006 | A1 |
20060287693 | Kraft et al. | Dec 2006 | A1 |
20060289640 | Mercure | Dec 2006 | A1 |
20060293607 | Alt | Dec 2006 | A1 |
20070000776 | Karube et al. | Jan 2007 | A1 |
20070002038 | Suzuki | Jan 2007 | A1 |
20070006636 | King et al. | Jan 2007 | A1 |
20070008113 | Spoonhower et al. | Jan 2007 | A1 |
20070016089 | Fischell et al. | Jan 2007 | A1 |
20070027386 | Such | Feb 2007 | A1 |
20070027388 | Chou | Feb 2007 | A1 |
20070038054 | Zhou | Feb 2007 | A1 |
20070049339 | Barak et al. | Mar 2007 | A1 |
20070055098 | Shimizu et al. | Mar 2007 | A1 |
20070060797 | Ball | Mar 2007 | A1 |
20070060800 | Drinan et al. | Mar 2007 | A1 |
20070066929 | Ferren et al. | Mar 2007 | A1 |
20070072156 | Kaufman et al. | Mar 2007 | A1 |
20070073353 | Rooney et al. | Mar 2007 | A1 |
20070088194 | Tahar | Apr 2007 | A1 |
20070096765 | Kagan | May 2007 | A1 |
20070106346 | Bergelson | May 2007 | A1 |
20070123772 | Euliano | May 2007 | A1 |
20070129622 | Bourget | Jun 2007 | A1 |
20070130287 | Kumar | Jun 2007 | A1 |
20070135691 | Zingelewicz et al. | Jun 2007 | A1 |
20070135803 | Belson | Jun 2007 | A1 |
20070142721 | Berner et al. | Jun 2007 | A1 |
20070156016 | Betesh | Jul 2007 | A1 |
20070160789 | Merical | Jul 2007 | A1 |
20070162089 | Mosesov | Jul 2007 | A1 |
20070162090 | Penner | Jul 2007 | A1 |
20070167495 | Brown et al. | Jul 2007 | A1 |
20070167848 | Kuo et al. | Jul 2007 | A1 |
20070172424 | Roser | Jul 2007 | A1 |
20070173701 | Al-Ali | Jul 2007 | A1 |
20070179347 | Tarassenko et al. | Aug 2007 | A1 |
20070179371 | Peyser et al. | Aug 2007 | A1 |
20070180047 | Dong et al. | Aug 2007 | A1 |
20070185393 | Zhou | Aug 2007 | A1 |
20070191002 | Ge | Aug 2007 | A1 |
20070196456 | Stevens | Aug 2007 | A1 |
20070207793 | Myer | Sep 2007 | A1 |
20070207858 | Breving | Sep 2007 | A1 |
20070208233 | Kovacs | Sep 2007 | A1 |
20070213659 | Trovato et al. | Sep 2007 | A1 |
20070237719 | Jones | Oct 2007 | A1 |
20070244370 | Kuo et al. | Oct 2007 | A1 |
20070244810 | Rudolph | Oct 2007 | A1 |
20070249946 | Kumar et al. | Oct 2007 | A1 |
20070255198 | Leong et al. | Nov 2007 | A1 |
20070255330 | Lee | Nov 2007 | A1 |
20070270672 | Hayter | Nov 2007 | A1 |
20070279217 | Venkatraman | Dec 2007 | A1 |
20070282174 | Sabatino | Dec 2007 | A1 |
20070282177 | Pilz | Dec 2007 | A1 |
20070291715 | Laroia et al. | Dec 2007 | A1 |
20070299480 | Hill | Dec 2007 | A1 |
20080004503 | Nisani et al. | Jan 2008 | A1 |
20080014866 | Lipowshi | Jan 2008 | A1 |
20080015421 | Penner | Jan 2008 | A1 |
20080015494 | Santini et al. | Jan 2008 | A1 |
20080015893 | Miller et al. | Jan 2008 | A1 |
20080020037 | Robertson et al. | Jan 2008 | A1 |
20080021519 | DeGeest | Jan 2008 | A1 |
20080021521 | Shah | Jan 2008 | A1 |
20080027679 | Shklarski | Jan 2008 | A1 |
20080033273 | Zhou | Feb 2008 | A1 |
20080033301 | Dellavecchia et al. | Feb 2008 | A1 |
20080038588 | Lee | Feb 2008 | A1 |
20080039700 | Drinan et al. | Feb 2008 | A1 |
20080045843 | Tsuji et al. | Feb 2008 | A1 |
20080046038 | Hill | Feb 2008 | A1 |
20080051647 | Wu et al. | Feb 2008 | A1 |
20080051667 | Goldreich | Feb 2008 | A1 |
20080051767 | Rossing et al. | Feb 2008 | A1 |
20080058614 | Banet | Mar 2008 | A1 |
20080062856 | Feher | Mar 2008 | A1 |
20080065168 | Bitton et al. | Mar 2008 | A1 |
20080074307 | Boric-Lubecke | Mar 2008 | A1 |
20080077015 | Botic-Lubecke | Mar 2008 | A1 |
20080077028 | Schaldach et al. | Mar 2008 | A1 |
20080077188 | Denker et al. | Mar 2008 | A1 |
20080077430 | Singer et al. | Mar 2008 | A1 |
20080091089 | Guillory et al. | Apr 2008 | A1 |
20080091114 | Min | Apr 2008 | A1 |
20080097549 | Colbaugh | Apr 2008 | A1 |
20080097917 | Dicks | Apr 2008 | A1 |
20080099366 | Niemic et al. | May 2008 | A1 |
20080103440 | Ferren et al. | May 2008 | A1 |
20080112885 | Okunev et al. | May 2008 | A1 |
20080114224 | Bandy et al. | May 2008 | A1 |
20080119705 | Patel | May 2008 | A1 |
20080119716 | Boric-Lubecke | May 2008 | A1 |
20080121825 | Trovato et al. | May 2008 | A1 |
20080137566 | Marholev | Jun 2008 | A1 |
20080139907 | Rao et al. | Jun 2008 | A1 |
20080140403 | Hughes et al. | Jun 2008 | A1 |
20080146871 | Arneson et al. | Jun 2008 | A1 |
20080146889 | Young | Jun 2008 | A1 |
20080146892 | LeBeouf | Jun 2008 | A1 |
20080154104 | Lamego | Jun 2008 | A1 |
20080166992 | Ricordi | Jul 2008 | A1 |
20080175898 | Jones et al. | Jul 2008 | A1 |
20080183245 | Van Oort | Jul 2008 | A1 |
20080188763 | John et al. | Aug 2008 | A1 |
20080188837 | Belsky | Aug 2008 | A1 |
20080194912 | Trovato et al. | Aug 2008 | A1 |
20080208009 | Shklarski | Aug 2008 | A1 |
20080214901 | Gehman | Sep 2008 | A1 |
20080214903 | Orbach | Sep 2008 | A1 |
20080214985 | Yanaki | Sep 2008 | A1 |
20080223936 | Mickle et al. | Sep 2008 | A1 |
20080243020 | Chou | Oct 2008 | A1 |
20080249360 | Li | Oct 2008 | A1 |
20080262320 | Schaefer et al. | Oct 2008 | A1 |
20080262336 | Ryu | Oct 2008 | A1 |
20080269664 | Trovato et al. | Oct 2008 | A1 |
20080275312 | Mosesov | Nov 2008 | A1 |
20080281636 | Jung et al. | Nov 2008 | A1 |
20080284599 | Zdeblick et al. | Nov 2008 | A1 |
20080288026 | Cross et al. | Nov 2008 | A1 |
20080288027 | Kroll | Nov 2008 | A1 |
20080294020 | Sapounas | Nov 2008 | A1 |
20080299197 | Toneguzzo et al. | Dec 2008 | A1 |
20080300572 | Rankers | Dec 2008 | A1 |
20080303638 | Nguyen | Dec 2008 | A1 |
20080303665 | Naik et al. | Dec 2008 | A1 |
20080306357 | Korman | Dec 2008 | A1 |
20080306359 | Zdeblick et al. | Dec 2008 | A1 |
20080306360 | Robertson et al. | Dec 2008 | A1 |
20080306362 | Davis | Dec 2008 | A1 |
20080311852 | Hansen | Dec 2008 | A1 |
20080312522 | Rowlandson | Dec 2008 | A1 |
20080316020 | Robertson | Dec 2008 | A1 |
20090006133 | Weinert | Jan 2009 | A1 |
20090009330 | Sakama et al. | Jan 2009 | A1 |
20090009332 | Nunez et al. | Jan 2009 | A1 |
20090024045 | Prakash | Jan 2009 | A1 |
20090024112 | Edwards et al. | Jan 2009 | A1 |
20090030293 | Cooper et al. | Jan 2009 | A1 |
20090030297 | Miller | Jan 2009 | A1 |
20090034209 | Joo | Feb 2009 | A1 |
20090043171 | Rule | Feb 2009 | A1 |
20090048498 | Riskey | Feb 2009 | A1 |
20090062634 | Say et al. | Mar 2009 | A1 |
20090062670 | Sterling | Mar 2009 | A1 |
20090062730 | Woo | Mar 2009 | A1 |
20090069642 | Gao | Mar 2009 | A1 |
20090069655 | Say et al. | Mar 2009 | A1 |
20090069656 | Say et al. | Mar 2009 | A1 |
20090069657 | Say et al. | Mar 2009 | A1 |
20090069658 | Say et al. | Mar 2009 | A1 |
20090076340 | Libbus et al. | Mar 2009 | A1 |
20090076343 | James | Mar 2009 | A1 |
20090076350 | Bly et al. | Mar 2009 | A1 |
20090076397 | Libbus et al. | Mar 2009 | A1 |
20090082645 | Hafezi et al. | Mar 2009 | A1 |
20090087483 | Sison | Apr 2009 | A1 |
20090088618 | Arneson | Apr 2009 | A1 |
20090099435 | Say et al. | Apr 2009 | A1 |
20090105561 | Boydon et al. | Apr 2009 | A1 |
20090110148 | Zhang | Apr 2009 | A1 |
20090112626 | Talbot | Apr 2009 | A1 |
20090124871 | Arshak | May 2009 | A1 |
20090131774 | Sweitzer | May 2009 | A1 |
20090134181 | Wachman et al. | May 2009 | A1 |
20090135886 | Robertson et al. | May 2009 | A1 |
20090142853 | Warrington et al. | Jun 2009 | A1 |
20090149708 | Hyde et al. | Jun 2009 | A1 |
20090149839 | Hyde et al. | Jun 2009 | A1 |
20090157113 | Marcotte | Jun 2009 | A1 |
20090157358 | Kim | Jun 2009 | A1 |
20090161602 | Matsumoto | Jun 2009 | A1 |
20090163789 | Say et al. | Jun 2009 | A1 |
20090171180 | Pering | Jul 2009 | A1 |
20090173628 | Say et al. | Jul 2009 | A1 |
20090177055 | Say et al. | Jul 2009 | A1 |
20090177056 | Say et al. | Jul 2009 | A1 |
20090177057 | Say et al. | Jul 2009 | A1 |
20090177058 | Say et al. | Jul 2009 | A1 |
20090177059 | Say et al. | Jul 2009 | A1 |
20090177060 | Say et al. | Jul 2009 | A1 |
20090177061 | Say et al. | Jul 2009 | A1 |
20090177062 | Say et al. | Jul 2009 | A1 |
20090177063 | Say et al. | Jul 2009 | A1 |
20090177064 | Say et al. | Jul 2009 | A1 |
20090177065 | Say et al. | Jul 2009 | A1 |
20090177066 | Say et al. | Jul 2009 | A1 |
20090182206 | Najafi | Jul 2009 | A1 |
20090182207 | Riskey et al. | Jul 2009 | A1 |
20090182212 | Say et al. | Jul 2009 | A1 |
20090182213 | Say et al. | Jul 2009 | A1 |
20090182214 | Say et al. | Jul 2009 | A1 |
20090182215 | Say et al. | Jul 2009 | A1 |
20090182388 | Von Arx | Jul 2009 | A1 |
20090187088 | Say et al. | Jul 2009 | A1 |
20090187089 | Say et al. | Jul 2009 | A1 |
20090187090 | Say et al. | Jul 2009 | A1 |
20090187091 | Say et al. | Jul 2009 | A1 |
20090187092 | Say et al. | Jul 2009 | A1 |
20090187093 | Say et al. | Jul 2009 | A1 |
20090187094 | Say et al. | Jul 2009 | A1 |
20090187095 | Say et al. | Jul 2009 | A1 |
20090187381 | King et al. | Jul 2009 | A1 |
20090192351 | Nishino | Jul 2009 | A1 |
20090192368 | Say et al. | Jul 2009 | A1 |
20090192369 | Say et al. | Jul 2009 | A1 |
20090192370 | Say et al. | Jul 2009 | A1 |
20090192371 | Say et al. | Jul 2009 | A1 |
20090192372 | Say et al. | Jul 2009 | A1 |
20090192373 | Say et al. | Jul 2009 | A1 |
20090192374 | Say et al. | Jul 2009 | A1 |
20090192375 | Say et al. | Jul 2009 | A1 |
20090192376 | Say et al. | Jul 2009 | A1 |
20090192377 | Say et al. | Jul 2009 | A1 |
20090192378 | Say et al. | Jul 2009 | A1 |
20090192379 | Say et al. | Jul 2009 | A1 |
20090198115 | Say et al. | Aug 2009 | A1 |
20090198116 | Say et al. | Aug 2009 | A1 |
20090198175 | Say et al. | Aug 2009 | A1 |
20090203964 | Shimizu et al. | Aug 2009 | A1 |
20090203971 | Sciarappa | Aug 2009 | A1 |
20090203972 | Heneghan | Aug 2009 | A1 |
20090203978 | Say et al. | Aug 2009 | A1 |
20090204265 | Hackett | Aug 2009 | A1 |
20090210164 | Say et al. | Aug 2009 | A1 |
20090216101 | Say et al. | Aug 2009 | A1 |
20090216102 | Say et al. | Aug 2009 | A1 |
20090227204 | Robertson et al. | Sep 2009 | A1 |
20090227876 | Tran | Sep 2009 | A1 |
20090227940 | Say et al. | Sep 2009 | A1 |
20090227941 | Say et al. | Sep 2009 | A1 |
20090227988 | Wood et al. | Sep 2009 | A1 |
20090228214 | Say et al. | Sep 2009 | A1 |
20090231125 | Baldus | Sep 2009 | A1 |
20090234200 | Husheer | Sep 2009 | A1 |
20090234203 | Arita | Sep 2009 | A1 |
20090243833 | Huang | Oct 2009 | A1 |
20090247836 | Cole et al. | Oct 2009 | A1 |
20090253960 | Takenaka et al. | Oct 2009 | A1 |
20090264714 | Chou | Oct 2009 | A1 |
20090264964 | Abrahamson | Oct 2009 | A1 |
20090265186 | Tarassenko et al. | Oct 2009 | A1 |
20090273467 | Elixmann | Nov 2009 | A1 |
20090277815 | Kohl et al. | Nov 2009 | A1 |
20090281539 | Selig | Nov 2009 | A1 |
20090287109 | Ferren et al. | Nov 2009 | A1 |
20090292194 | Libbus et al. | Nov 2009 | A1 |
20090295548 | Ronkka | Dec 2009 | A1 |
20090296677 | Mahany | Dec 2009 | A1 |
20090301925 | Alloro et al. | Dec 2009 | A1 |
20090303920 | Mahany | Dec 2009 | A1 |
20090306633 | Trovato et al. | Dec 2009 | A1 |
20090312619 | Say et al. | Dec 2009 | A1 |
20090318303 | Delamarche et al. | Dec 2009 | A1 |
20090318761 | Rabinovitz | Dec 2009 | A1 |
20090318779 | Tran | Dec 2009 | A1 |
20090318783 | Rohde | Dec 2009 | A1 |
20090318793 | Datta | Dec 2009 | A1 |
20100001841 | Cardullo | Jan 2010 | A1 |
20100006585 | Flowers et al. | Jan 2010 | A1 |
20100010330 | Rankers | Jan 2010 | A1 |
20100015584 | Singer et al. | Jan 2010 | A1 |
20100033324 | Shimizu et al. | Feb 2010 | A1 |
20100036269 | Ferren et al. | Feb 2010 | A1 |
20100049004 | Edman et al. | Feb 2010 | A1 |
20100049006 | Magar | Feb 2010 | A1 |
20100049012 | Dijksman et al. | Feb 2010 | A1 |
20100049069 | Tarassenko et al. | Feb 2010 | A1 |
20100056878 | Partin | Mar 2010 | A1 |
20100056891 | Say et al. | Mar 2010 | A1 |
20100056939 | Tarassenko et al. | Mar 2010 | A1 |
20100057041 | Hayter | Mar 2010 | A1 |
20100062709 | Kato | Mar 2010 | A1 |
20100063438 | Bengtsson | Mar 2010 | A1 |
20100063841 | D'Ambrosia et al. | Mar 2010 | A1 |
20100069002 | Rong | Mar 2010 | A1 |
20100069717 | Hafezi et al. | Mar 2010 | A1 |
20100082367 | Hains et al. | Apr 2010 | A1 |
20100099967 | Say et al. | Apr 2010 | A1 |
20100099968 | Say et al. | Apr 2010 | A1 |
20100099969 | Say et al. | Apr 2010 | A1 |
20100100077 | Rush | Apr 2010 | A1 |
20100100078 | Say et al. | Apr 2010 | A1 |
20100100237 | Ratnakar | Apr 2010 | A1 |
20100106001 | Say et al. | Apr 2010 | A1 |
20100118853 | Godfrey | May 2010 | A1 |
20100131434 | Magent | May 2010 | A1 |
20100139672 | Kroll et al. | Jun 2010 | A1 |
20100160742 | Seidl et al. | Jun 2010 | A1 |
20100168659 | Say et al. | Jul 2010 | A1 |
20100179398 | Say et al. | Jul 2010 | A1 |
20100183199 | Smith et al. | Jul 2010 | A1 |
20100191073 | Tarassenko et al. | Jul 2010 | A1 |
20100203394 | Bae et al. | Aug 2010 | A1 |
20100210299 | Gorbachov | Aug 2010 | A1 |
20100217100 | LeBoeuf et al. | Aug 2010 | A1 |
20100222652 | Cho | Sep 2010 | A1 |
20100228113 | Solosko | Sep 2010 | A1 |
20100233026 | Ismagliov et al. | Sep 2010 | A1 |
20100234706 | Gilland | Sep 2010 | A1 |
20100234715 | Shin | Sep 2010 | A1 |
20100234914 | Shen | Sep 2010 | A1 |
20100245091 | Singh | Sep 2010 | A1 |
20100249541 | Geva et al. | Sep 2010 | A1 |
20100249881 | Corndorf | Sep 2010 | A1 |
20100256461 | Mohamedali | Oct 2010 | A1 |
20100259543 | Tarassenko et al. | Oct 2010 | A1 |
20100268048 | Say et al. | Oct 2010 | A1 |
20100268049 | Say et al. | Oct 2010 | A1 |
20100268050 | Say et al. | Oct 2010 | A1 |
20100268288 | Hunter et al. | Oct 2010 | A1 |
20100274111 | Say et al. | Oct 2010 | A1 |
20100280345 | Say et al. | Nov 2010 | A1 |
20100280346 | Say et al. | Nov 2010 | A1 |
20100295694 | Kauffman et al. | Nov 2010 | A1 |
20100298668 | Hafezi et al. | Nov 2010 | A1 |
20100298730 | Tarassenko et al. | Nov 2010 | A1 |
20100299155 | Findlay et al. | Nov 2010 | A1 |
20100312188 | Robertson et al. | Dec 2010 | A1 |
20100312577 | Goodnow et al. | Dec 2010 | A1 |
20100312580 | Tarassenko et al. | Dec 2010 | A1 |
20100332443 | Gartenberg | Dec 2010 | A1 |
20110004079 | Ali et al. | Jan 2011 | A1 |
20110009715 | O'Reilly et al. | Jan 2011 | A1 |
20110021983 | Jurson | Jan 2011 | A1 |
20110029622 | Walker et al. | Feb 2011 | A1 |
20110050431 | Hood et al. | Mar 2011 | A1 |
20110054265 | Hafezi et al. | Mar 2011 | A1 |
20110065983 | Hafezi et al. | Mar 2011 | A1 |
20110077660 | Janik et al. | Mar 2011 | A1 |
20110081860 | Brown et al. | Apr 2011 | A1 |
20110105864 | Robertson et al. | May 2011 | A1 |
20110112686 | Nolan et al. | May 2011 | A1 |
20110124983 | Kroll et al. | May 2011 | A1 |
20110144470 | Mazar et al. | Jun 2011 | A1 |
20110160549 | Saroka et al. | Jun 2011 | A1 |
20110212782 | Thompson et al. | Sep 2011 | A1 |
20110224912 | Bhavaraju et al. | Sep 2011 | A1 |
20110230732 | Edman et al. | Sep 2011 | A1 |
20110237924 | McGusty et al. | Sep 2011 | A1 |
20110270112 | Manera et al. | Nov 2011 | A1 |
20110270135 | Dooley et al. | Nov 2011 | A1 |
20110279963 | Kumar et al. | Nov 2011 | A1 |
20120024889 | Robertson et al. | Feb 2012 | A1 |
20120029309 | Paquet et al. | Feb 2012 | A1 |
20120032816 | Cho et al. | Feb 2012 | A1 |
20120062371 | Radivojevic et al. | Mar 2012 | A1 |
20120071743 | Todorov et al. | Mar 2012 | A1 |
20120083715 | Yuen et al. | Apr 2012 | A1 |
20120089000 | Bishay et al. | Apr 2012 | A1 |
20120101396 | Solosko et al. | Apr 2012 | A1 |
20120116184 | Shieh | May 2012 | A1 |
20120179004 | Roesicke et al. | Jul 2012 | A1 |
20120197144 | Christ et al. | Aug 2012 | A1 |
20120214140 | Brynelson et al. | Aug 2012 | A1 |
20120265544 | Hwang et al. | Oct 2012 | A1 |
20120310070 | Kumar et al. | Dec 2012 | A1 |
20120316413 | Liu et al. | Dec 2012 | A1 |
20130002423 | Robertson et al. | Jan 2013 | A1 |
20130030259 | Thomsen et al. | Jan 2013 | A1 |
20130057385 | Murakami et al. | Mar 2013 | A1 |
20130060115 | Gehman et al. | Mar 2013 | A1 |
20130073312 | Thompson et al. | Mar 2013 | A1 |
20130117696 | Robertson et al. | May 2013 | A1 |
20130171596 | French | Jul 2013 | A1 |
20130185228 | Dresner | Jul 2013 | A1 |
20130196012 | Dill | Aug 2013 | A1 |
20130275296 | Tietzen et al. | Oct 2013 | A1 |
20130328416 | Whitworth et al. | Dec 2013 | A1 |
20130338452 | Robertson et al. | Dec 2013 | A1 |
20140004492 | O'Reilly et al. | Jan 2014 | A1 |
20140039445 | Austin et al. | Feb 2014 | A1 |
20140051965 | Zdeblick et al. | Feb 2014 | A1 |
20140203950 | Zdeblick et al. | Jul 2014 | A1 |
20140280125 | Bhardwaj et al. | Sep 2014 | A1 |
20140308930 | Tran | Oct 2014 | A1 |
20140315170 | Ionescu et al. | Oct 2014 | A1 |
20140349256 | Connor | Nov 2014 | A1 |
20140374276 | Guthrie et al. | Dec 2014 | A1 |
20150051465 | Robertson et al. | Feb 2015 | A1 |
20150080677 | Thompson et al. | Mar 2015 | A1 |
20150080678 | Frank et al. | Mar 2015 | A1 |
20150080679 | Frank et al. | Mar 2015 | A1 |
20150080680 | Zdeblick et al. | Mar 2015 | A1 |
20150080681 | Hafezi et al. | Mar 2015 | A1 |
20150127737 | Thompson et al. | May 2015 | A1 |
20150127738 | Thompson et al. | May 2015 | A1 |
20150149375 | Thompson et al. | May 2015 | A1 |
20150165313 | Thompson et al. | Jun 2015 | A1 |
20150171924 | Zdeblick | Jun 2015 | A1 |
20150182463 | Hafezi et al. | Jul 2015 | A1 |
20150193593 | Zdeblick et al. | Jul 2015 | A1 |
20150230728 | Hafezi et al. | Aug 2015 | A1 |
20150318901 | Robertson et al. | Nov 2015 | A1 |
20150365115 | Arne et al. | Dec 2015 | A1 |
20160155316 | Hafezi et al. | Jun 2016 | A1 |
20170215761 | Zdeblick | Aug 2017 | A1 |
20170270779 | Zdeblick et al. | Sep 2017 | A1 |
20170290513 | O'Reilly et al. | Oct 2017 | A1 |
20170303818 | Behzadi et al. | Oct 2017 | A1 |
20180026680 | Shirvani et al. | Jan 2018 | A1 |
20180184698 | Arne et al. | Jul 2018 | A1 |
20190133958 | Hafezi et al. | May 2019 | A1 |
20190158151 | Shirvani et al. | May 2019 | A1 |
Number | Date | Country |
---|---|---|
2953847 | Nov 2006 | CA |
1588649 | Mar 2005 | CN |
2748032 | Dec 2005 | CN |
1991868 | Jul 2007 | CN |
101005470 | Jul 2007 | CN |
201076456 | Jun 2008 | CN |
101524267 | Sep 2009 | CN |
10313005 | Oct 2004 | DE |
0344939 | Dec 1989 | EP |
0526166 | Feb 1993 | EP |
1199670 | Apr 2002 | EP |
1246356 | Oct 2002 | EP |
1342447 | Sep 2003 | EP |
1534054 | May 2005 | EP |
1702553 | Sep 2006 | EP |
1098591 | Jan 2007 | EP |
1789128 | May 2007 | EP |
2143369 | Jan 2010 | EP |
775071 | May 1957 | GB |
2432862 | Jun 2007 | GB |
172917 | Jun 2010 | IL |
2000506410 | May 1912 | JP |
S6117949 | Jan 1986 | JP |
S63280393 | Nov 1988 | JP |
H01285247 | Nov 1989 | JP |
05228128 | Sep 1993 | JP |
H0884779 | Apr 1996 | JP |
09330159 | Dec 1997 | JP |
1014898 | Jan 1998 | JP |
H11195415 | Jul 1999 | JP |
2001078974 | Mar 2001 | JP |
2002224053 | Aug 2002 | JP |
2002263185 | Sep 2002 | JP |
2002282218 | Oct 2002 | JP |
2002282219 | Oct 2002 | JP |
2002291684 | Oct 2002 | JP |
2003210395 | Jul 2003 | JP |
3454525 | Oct 2003 | JP |
2003325440 | Nov 2003 | JP |
2004007187 | Jan 2004 | JP |
2004507188 | Mar 2004 | JP |
2004134384 | Apr 2004 | JP |
2004274452 | Sep 2004 | JP |
2004313242 | Nov 2004 | JP |
2004318534 | Nov 2004 | JP |
2004-538572 | Dec 2004 | JP |
2004364016 | Dec 2004 | JP |
2005031840 | Feb 2005 | JP |
2005073886 | Mar 2005 | JP |
2005304880 | Apr 2005 | JP |
2005124708 | May 2005 | JP |
2005148021 | Jun 2005 | JP |
2005152037 | Jun 2005 | JP |
2005287691 | Oct 2005 | JP |
2005532841 | Nov 2005 | JP |
2005532849 | Nov 2005 | JP |
2005343515 | Dec 2005 | JP |
2006006377 | Jan 2006 | JP |
2006509574 | Mar 2006 | JP |
2006177699 | Jul 2006 | JP |
2006187611 | Jul 2006 | JP |
2006278091 | Oct 2006 | JP |
2006346000 | Dec 2006 | JP |
3876573 | Jan 2007 | JP |
2007151809 | Jun 2007 | JP |
2007159631 | Jun 2007 | JP |
2007-212421 | Aug 2007 | JP |
2007200739 | Aug 2007 | JP |
2007313340 | Dec 2007 | JP |
2007330677 | Dec 2007 | JP |
2008011865 | Jan 2008 | JP |
2008501415 | Jan 2008 | JP |
2008176434 | Jul 2008 | JP |
2008191955 | Aug 2008 | JP |
2008289724 | Dec 2008 | JP |
2009034345 | Feb 2009 | JP |
2009050541 | Mar 2009 | JP |
2009061236 | Mar 2009 | JP |
2009065726 | Mar 2009 | JP |
2010-533546 | Nov 2010 | JP |
2011015817 | Jan 2011 | JP |
2011519583 | Jul 2011 | JP |
2016-515022 | May 2016 | JP |
20020015907 | Mar 2002 | KR |
20020061744 | Jul 2002 | KR |
200600977523 | Jul 2006 | KR |
100927471 | Nov 2009 | KR |
20110137001 | Dec 2011 | KR |
10-2012-099995 | Sep 2012 | KR |
200301864 | Jul 2003 | TW |
553735 | Sep 2003 | TW |
200724094 | Jul 2007 | TW |
200812556 | Mar 2008 | TW |
201120673 | Jun 2011 | TW |
WO1988002237 | Apr 1988 | WO |
WO1992021307 | Dec 1992 | WO |
WO1993008734 | May 1993 | WO |
WO1993019667 | Oct 1993 | WO |
WO1994001165 | Jan 1994 | WO |
WO9516393 | Jun 1995 | WO |
WO1997014112 | Apr 1997 | WO |
WO1997039963 | Oct 1997 | WO |
WO1998043537 | Oct 1998 | WO |
WO1999037290 | Jul 1999 | WO |
WO1999059465 | Nov 1999 | WO |
WO2000033246 | Jun 2000 | WO |
WO2001000085 | Jan 2001 | WO |
WO2001047466 | Jul 2001 | WO |
WO2001049364 | Jul 2001 | WO |
WO2001074011 | Oct 2001 | WO |
WO2001080731 | Nov 2001 | WO |
0197092 | Dec 2001 | WO |
WO0235997 | May 2002 | WO |
WO2002045489 | Jun 2002 | WO |
WO2002058330 | Jul 2002 | WO |
WO2002062276 | Aug 2002 | WO |
WO2002087681 | Nov 2002 | WO |
WO2002095351 | Nov 2002 | WO |
WO2003005877 | Jan 2003 | WO |
WO2003050643 | Jun 2003 | WO |
WO2003068061 | Aug 2003 | WO |
WO2004014225 | Feb 2004 | WO |
WO2004019172 | Mar 2004 | WO |
WO2004039256 | May 2004 | WO |
WO2004059551 | Jul 2004 | WO |
WO2004066833 | Aug 2004 | WO |
WO2004066834 | Aug 2004 | WO |
WO2004066903 | Aug 2004 | WO |
WO2004068748 | Aug 2004 | WO |
WO2004068881 | Aug 2004 | WO |
WO2004075751 | Sep 2004 | WO |
WO2004109316 | Dec 2004 | WO |
WO2004110555 | Dec 2004 | WO |
WO2005011237 | Feb 2005 | WO |
WO2005020023 | Mar 2005 | WO |
WO2005024687 | Mar 2005 | WO |
WO2005041767 | May 2005 | WO |
WO2005047837 | May 2005 | WO |
WO2005051166 | Jun 2005 | WO |
WO2005053517 | Jun 2005 | WO |
WO2005069887 | Aug 2005 | WO |
WO2005082436 | Sep 2005 | WO |
WO2005083621 | Sep 2005 | WO |
WO2005110238 | Nov 2005 | WO |
WO2005117697 | Dec 2005 | WO |
WO2006009404 | Jan 2006 | WO |
WO2006016370 | Feb 2006 | WO |
WO2006021932 | Mar 2006 | WO |
WO2006027586 | Mar 2006 | WO |
WO2006028347 | Mar 2006 | WO |
WO2006035351 | Apr 2006 | WO |
WO2006037802 | Apr 2006 | WO |
WO2006046648 | May 2006 | WO |
WO2006055892 | May 2006 | WO |
WO2006055956 | May 2006 | WO |
WO2006059338 | Jun 2006 | WO |
WO2006075016 | Jul 2006 | WO |
WO2006100620 | Sep 2006 | WO |
WO2006104843 | Oct 2006 | WO |
WO2006109072 | Oct 2006 | WO |
WO2006123346 | Nov 2006 | WO |
WO2006116718 | Nov 2006 | WO |
WO2006119345 | Nov 2006 | WO |
WO2006127355 | Nov 2006 | WO |
WO2007001724 | Jan 2007 | WO |
WO2007001742 | Jan 2007 | WO |
WO2007013952 | Feb 2007 | WO |
WO2007014084 | Feb 2007 | WO |
WO2007014527 | Feb 2007 | WO |
WO2007021496 | Feb 2007 | WO |
WO2007027660 | Mar 2007 | WO |
WO2007028035 | Mar 2007 | WO |
WO2007036687 | Apr 2007 | WO |
WO2007036741 | Apr 2007 | WO |
WO2007036746 | Apr 2007 | WO |
WO2007040878 | Apr 2007 | WO |
WO2007067054 | Jun 2007 | WO |
WO2007071180 | Jun 2007 | WO |
WO2007096810 | Aug 2007 | WO |
WO2007101141 | Sep 2007 | WO |
WO2007115087 | Oct 2007 | WO |
WO2007120946 | Oct 2007 | WO |
WO2007123923 | Nov 2007 | WO |
WO2007127316 | Nov 2007 | WO |
WO2007127879 | Nov 2007 | WO |
WO2007127945 | Nov 2007 | WO |
WO2007128165 | Nov 2007 | WO |
WO2007130491 | Nov 2007 | WO |
WO2007133526 | Nov 2007 | WO |
WO2007143535 | Dec 2007 | WO |
WO2007149546 | Dec 2007 | WO |
WO2008008281 | Jan 2008 | WO |
WO2008012700 | Jan 2008 | WO |
WO2008030482 | Mar 2008 | WO |
WO2008039030 | Apr 2008 | WO |
WO2008052136 | May 2008 | WO |
WO2008061138 | May 2008 | WO |
WO2008063626 | May 2008 | WO |
WO2008066617 | Jun 2008 | WO |
WO2008076464 | Jun 2008 | WO |
WO2008085131 | Jul 2008 | WO |
WO2008089232 | Jul 2008 | WO |
WO2008091683 | Jul 2008 | WO |
WO2008095183 | Aug 2008 | WO |
WO2008097652 | Aug 2008 | WO |
WO2008101107 | Aug 2008 | WO |
WO2008112577 | Sep 2008 | WO |
WO2008112578 | Sep 2008 | WO |
WO2008120156 | Oct 2008 | WO |
WO2008133394 | Nov 2008 | WO |
WO2008134185 | Nov 2008 | WO |
WO2008150633 | Dec 2008 | WO |
WO2009001108 | Dec 2008 | WO |
WO2009005759 | Jan 2009 | WO |
WO2009006615 | Jan 2009 | WO |
2009021378 | Feb 2009 | WO |
WO2009022343 | Feb 2009 | WO |
WO2009029453 | Mar 2009 | WO |
WO2009032381 | Mar 2009 | WO |
WO2009036334 | Mar 2009 | WO |
2009-513183 | Apr 2009 | WO |
WO2009051829 | Apr 2009 | WO |
WO2009051830 | Apr 2009 | WO |
WO2009063377 | May 2009 | WO |
WO2009081348 | Jul 2009 | WO |
WO2009111664 | Sep 2009 | WO |
WO2009146082 | Dec 2009 | WO |
2010005877 | Jan 2010 | WO |
WO2010009100 | Jan 2010 | WO |
WO2010011833 | Jan 2010 | WO |
WO2010019778 | Feb 2010 | WO |
WO2010057049 | May 2010 | WO |
WO2010075115 | Jul 2010 | WO |
WO2010080765 | Jul 2010 | WO |
WO2010080843 | Jul 2010 | WO |
WO2010107563 | Sep 2010 | WO |
WO2010107980 | Sep 2010 | WO |
WO2010115194 | Oct 2010 | WO |
WO2010132331 | Nov 2010 | WO |
WO2010135516 | Nov 2010 | WO |
WO2011024560 | Mar 2011 | WO |
WO2011068963 | Jun 2011 | WO |
WO2011133799 | Oct 2011 | WO |
WO2011159336 | Dec 2011 | WO |
WO2011159337 | Dec 2011 | WO |
WO2011159338 | Dec 2011 | WO |
WO2011159339 | Dec 2011 | WO |
WO2012104657 | Aug 2012 | WO |
WO2012158190 | Nov 2012 | WO |
WO2013012869 | Jan 2013 | WO |
2013070914 | May 2013 | WO |
WO2015112603 | Jul 2015 | WO |
Entry |
---|
AADE, “AADE 37th Annual Meeting San Antonio Aug. 4-7, 2010” American Association of Diabetes Educators Aug. 2010; http://www.diabeteseducator.org/annualmeeting/2010/index.html; 2 pp. |
Arshak et al., A Review and Adaptation of Methods of Object Tracking to Telemetry Capsules IC-Med; Jan. 2007 vol. 1, No. 1, Issue 1, 12pp. |
“ASGE Technology Status Evaluation Report: wireless capsule endoscopy” American Soc. For Gastrointestinal Endoscopy; Apr. 2006 vol. 63, No. 4; 7 pp. |
Au-Yeung, K., et al., “A Networked System for Self-Management of Drug Therapy and Wellness”, Wireless Health '10, Oct. 5-7, 2010, San Diego, 9 pages. |
Aydin et al., “Design and implementation considerations for an advanced wireless interface in miniaturized integrated sensor Microsystems” Sch. of Eng. & Electron., Edinburgh Univ., UK; Sep. 2003; Abstract Only. |
Barrie, Heidelberg pH capsule gastric analysis. Texbook of Natural Medicine, (1992), Pizzorno, Murray & Barrie. |
Baskiyar, S. “A Real-time Fault Tolerant Intra-body Network” Dept. of Comp. Sci & Soft Eng; Auburn University; Proceedings of the 27th Annual IEEE Conference; 0742-1303/02 (2002) IEEE; 6 pp. |
Bohidar et al., “Dielectric Behavior of Gelatin Solutions and Gels” Colloid Polym Sci (1998) 276:81-86. |
Brock, “Smart Medicine: The Application of Auto-ID Technology to Healthcare” Auto-ID Labs (2002) http://www.autoidlabs.org/uploads/media/MIT-AUTOID-WH-010.pdf. |
Carlson et al., “Evaluation of a non-invasive respiratory monitoring system for sleeping subjects” Physiological Measurement (1999) 20(1): 53. |
Consolvo, Sunny et al., “Design Requirement for Technologies that Encourage Physical Activity,” CHI 2006 Proceedings, Designing for Tangible Interactions, Apr. 22, 2006, Montreal, Quebec, Canada, pp. 457-466. |
Coury, L. “Conductance Measurement Part 1: Theory”; Current Separations, 18:3 (1999) p. 91-96. |
Delvaux et al., “Capsule endoscopy: Technique and indications” Clinical Gastoenterology; Oct. 2008 vol. 22, Issue 5, 1pp. (Abstract Only). |
Description of ePatch Technology Platform for ECG and EMG, located it http://www.madebydelta.com/imported/images/DELTA_Web/documents/ME/ePatch_ECG_EMG.pdf, Dated Sep. 2, 2010. |
Dhar et al., “Electroless nickel plated contacts on porous silicon” Appl. Phys. Lett. 68 (10) pp. 1392-1393 (1996). |
Eldek A., “Design of double dipole antenna with enhanced usable bandwidth for wideband phased array applications” Progress in Electromagnetics Research PIER 59, 1-15 (2006). |
Evanczuk, S., “PIC MCU software library uses human body for secure communications link”; EDN Network; edn.com; Retrieved from internet Jun. 19, 2013 at http://www.edn.com/electronics-products/other/4407842/PIC-MCU-software-library-uses-human-body-for-secure-communications-link; Feb. 26, 2013; 5 pp. |
Fawaz et al., “Enhanced Telemetry System using CP-QPSK Band- Pass Modulation Technique Suitable for Smart Pill Medical Application” IFIP IEEE Dubai Conference Apr. 2008; http://www.asic.fh-offenburg.de/downloads/ePille/IFIP_IEEE_Dubai_Conference.pdf. |
Ferguson et al., “Dielectric Constant Studies III Aqueous Gelatin Solutions” J. Chem. Phys. 2, 94 (1934) p. 94-98. |
Ferguson et al., “Wireless communication with implanted medical devices using the conductive properties of the body,” Expert Rev Med Devices, Jul. 2011, 8(4): 427-433. |
Furse C. M., “Dipole Antennas” J. Webster (ed). Wiley Encyclopedia of Electrical and Electronics Engineering (1999) p. 575-581. |
Gaglani S. “Put Your Phone, Or Skin, on Vibrate” MedGadget; Mar. 2012 http://medgadget.com/2012/03/put-your-phone-or-skin-on-vibrate.html 8pp. |
Gilson, D.R. “Molecular dynamics simulation of dipole interactions”, Department of Physics, Hull University, Dec. 2002, p. 1-43. |
Given Imaging, “Agile Patency Brochure” (2006) http://www.inclino.no/documents/AgilePatencyBrochure_Global_GMB-0118-01.pdf; 4pp. |
Gonzalez-Guillaumin et al., “Ingestible capsule for impedance and pH monitoring in the esophagus” IEEE Trans Biomed Eng; Dec. 2007 54(12) 1pp. (Abstract Only). |
Greene, “Edible RFID microchip monitor can tell if you take your medicine” Bloomberg Businessweek; Mar. 2010 2 pp.; http://www.businessweek.com/idg/2010-03-31/edible-rfid-microchip-monitor-can-tell-if-you-take-your-medicine.html. |
Greene, “Medicaid Efforts to Incentivize Healthy Behaviours”, Center for Health Care Strategies, Inc., Resource Paper, Jul. 2007. |
Halthion Medical Technologies “Providing Ambulatory Medical Devices Which Monitor, Measure and Record” webpage. Online website: http://www.halthion.com/; downloaded May 30, 2012; 2 pp. |
Heydari et al., “Analysis of the PLL jitter due to power/ground and substrate noise”; IEEE Transactions on Circuits and Systems (2004) 51(12): 2404-16. |
Hoeksma, J. “New ‘smart pill’ to track adherence” E-Health-lnsider; http://www.e-health-insider.com/news/5910/new_‘smart_pill’_monitors_medicines; May 17, 2010 (2010); 1pp. |
Hoover et al., “Rx for health: Engineers design pill that signals it has been swallowed” University of Florida News; Mar. 2010 2pp.; http://news.ufl.edu/2010/03/31/antenna-pill-2/. |
Hotz “The Really Smart Phone” The Wall Street Journal, What They Know (2011); 6 pp.; http://online.wsj.com/article/SB10001424052748704547604576263261679848814.html?mod=djemTECH_t. |
Intromedic, MicroCam Innovative Capsule Endoscope Pamphlet. (2006) 8 pp (http://www.intromedic.com/en/product/productinfo.asp). |
ISFET—Ion Sensitive Field-Effect Transistor; Microsens S.A. pdf document. First cited by Examiner in Office Action dated Jun. 13, 2011 for U.S. Appl. No. 12/238,345; 4pp. |
Jimbo et al., “Gastric-fluid-utilized micro battery for micro medical devices” The Sixth International Workshop on Micro and Nanotechnology for Power Geneartion and Energy Conservation Applications, (2006) pp. 97-100. |
Jung, S. “Dissolvable ‘Transient Electronics’ Will Be Good For Your Body and the Environment” MedGadget; Oct. 1, 2012; Onlne website: http://medgadget.com/2012/10/dissolvable-transient-electronics-will-be-good-for-your-body-and-the-environment.html; downloaded Oct. 24, 2012; 4 pp. |
Juvenile Diabetes Research Foundation International (JDRF), “Artificial Pancreas Project” Jun. 2010; http://www.artificialpancreasproject.com/; 3 pp. |
Kamada K., “Electrophoretic deposition assisted by soluble anode” Materials Letters 57 (2003) 2348-2351. |
Kendle, Earl R. and Morris, Larry A., “Preliminary Studies in the Development of a Gastric Battery for Fish” (1964). Nebraska Game and Parks Commission White Papers, Conference Presentations, & Manuscripts. Paper 22. p. 1-6. |
Kim et al., “A Semi-Interpenetrating Network System for a Polymer Membrane”; Eur. Polym. J. vol. 33 No. 7; pp. 1009-1014 (1997). |
Li, P-Y, et al. “An electrochemical intraocular drug delivery device”, Sensors and Actuators A 143; p. 41-48.; Jul. 2007. |
Lifescan, “OneTouch UltraLink™” http://www.lifescan.com/products/meters/ultralink; Jul. 2010 2 pp. |
Lin et al., “Do Physiological Data Relate to Traditional Usability Indexes?” Proceedings of OZCHI 2005, Canberra, Australia (2005) 10 pp. |
Mackay et al., “Radio Telemetering from within the Body” Inside Information is Revealed by Tiny Transmitters that can be Swallowed or Implanted in Man or Animal Science (1991) 1196-1202; 134; American Association for the Advancement of Science, Washington D.C. |
Mackay et al., “Endoradiosonde” Nature, (1957) 1239-1240, 179 Nature Publishing Group. |
Mandryk et al., “A physiological approach for continuously modeling user emotion in interactive play environments” Proceedings of Measuring Behavior (2008) (Maastrichtm The Netherlandsm Aug. 26-29) 2 pp. |
Mandryk et al., “Objectively Evaluating Entertainment Technology” Simon Fraser University; CHI (2004) ACM 1-58113-703-6/04/0004; 2 pp. |
McDermott-Wells, P., “What is Bluetooth?”, IEEE Potentials, IEEE, New York, NY, vol. 23, No. 5, Dec. 1, 2004, pp. 33-35. |
McKenzie et al., “Validation of a new telemetric core temperature monitor” J. Therm. Biol. (2004) 29(7-8):605-11. |
Medtronic, “CareLink Therapy Management Software for Diabetes” Jul. 2010; https://carelink.minimed.com/patient/entry.jsp?bhcp=1; 1 pp. |
Medtronic, “Carelink™ USB” (2008) http://www.medtronicdiabetes.com/pdf/carelink_usb_factsheet.pdf 2pp. |
Medtronic “The New MiniMed Paradigm® REAL-Time Revel™ System” Aug. 2010 http://www.medtronicdiabetes.com/products/index.html; 2 pp. |
Medtronic, “MINI MED Paradigm ® Revel ™ Insulin Pump” Jul. 2010 http://www.medtronicdiabetes.com/products/insulinpumps/index.html; 2 pp. |
Medtronic, Mini Med Paradigm™ Veo™ System: Factsheet (2010). http://www.medtronic-diabetes.com.au/downloads/Paradigm%20Veo%20Factsheet.pdf; 4 pp. |
Melanson, “Walkers swallow RFID pills for science” Engadget; Jul. 2008; http://www.engadget.com/2008/07/29/walkers-swallow-rfid-pills-for-science/. |
Minimitter Co. Inc. “Actiheart” Traditional 510(k) Summary. Sep. 27, 2005. |
Minimiter Co. Inc. Noninvasive technology to help your studies succeed. Mini Mitter.com Mar. 31, 2009. |
Mini Mitter Co, Inc. 510(k) Premarket Notification Mini-Logger for Diagnostic Spirometer. Sep. 21, 1999. |
Mini Mitter Co, Inc. 510(k) Premarket Notification for VitalSense. Apr. 22, 2004. |
Minimitter Co. Inc. VitalSense Integrated Physiological Monitoring System. Product Description. Jul. 2005. |
Minimitter Co. Inc. VitalSense Wireless Vital Signs Monitoring. Temperatures.com Mar. 31, 2009. |
Mojaverian et al., “Estimation of gastric residence time of the Heidelberg capsule in humans: effect of varying food composition” Gastroenterology (1985) 89:(2): 392-7. |
O'Brien et al., “The Production and Characterization of Chemically Reactive Porous Coatings of Zirconium Via Unbalanced Magnetron Sputtering” Surface and Coatings Technology (1996) 86-87; 200-206. |
Owano, N., “Study proposes smart sutures with sensors for wounds” PHYS.ORG. Aug. 2012. http://phys.org/news/2012-08-smart-sutures-sensors-wounds.html; 2pp. |
“PALO Bluetooth Baseband” PALO Bluetooth Resource Center; Retrieved from internet Dec. 12, 2012 at URL:http://palowireless.com/bluearticles/baseband.asp; first cited in Office Action dated Jan. 17, 2013 for EP08853901.0 (2013); 6pp. |
Park, “Medtronic to Buy MiniMed for $3.7 Billion” (2001) HomeCare; http://homecaremag.com/mag/medical_medtronic_buy_minimed/; 2 pp. |
Platt, D., “Modulation and Deviation” AE6EO, Foothills Amateur Radio Society; Oct. 26, 2007; 61 pp. |
Radio Antennae, http://www.erikdeman.de/html/sail018h.htm; (2008) 5 pages. |
“RFID “pill” monitors marchers” RFID News; Jul. 2008 http://www.rfidnews.org/2008/07/23/rfid-pill-monitors-marchers/. |
Rolison et al., “Electrically conductive oxide aerogels: new materials in electrochemistry” J. Mater. Chem. (2001) 1, 963-980. |
Roulstone, et al., “Studies on Polymer Latex Films: 1. A study of latex film morphology” Polymer International 24 (1991) pp. 87-94. |
Sanduleanu et al., “Octave tunable, highly linear, RC-ring oscillator with differential fine-coarse tuning, quadrature outputs and amplitude control for fiber optic transceivers” (2002) IEEE MTT-S International Microwave Symposium Digest 545-8. |
Santini, J.T. et al., “Microchips as controlled drug delivery-devices”, Agnew. Chem. Int. Ed. (2000), vol. 39, p. 2396-2407. |
“SensiVida minimally invasive clinical systems” Investor Presentation Oct. 2009 28pp; http://www.sensividamedtech.com/SensiVidaGeneralOctober09.pdf. |
Sharma, et al., “The Future is Wireless: Advances in Wireless Diagnostic and Therapeutic Technologies in Gastoenterology,” Gastroenterology, Elesevier, Philadelphia, PA, vol. 137, No. 2, Aug. 1, 2009, pp. 434-439. |
Shawgo, R.S. et al. “BioMEMS from drug delivery”, Current Opinion in Solid State and Material Science 6; May 2002, p. 329-334. |
Shin et al., “A Simple Route to Metal Nanodots and Nanoporous Metal Films”; Nano Letters, vol. 2, No. 9 (2002) pp. 933-936. |
Shrivas et al., “A New Platform for Bioelectronics-Electronic Pill”, Cummins College, (2010).; http://www.cumminscollege.org/downloads/electronics_and_telecommunication/Newsletters/Current%20Newsletters.pdf; First cited in third party client search conducted by Patent Eagle Search May 18, 2010 (2010). |
“Smartlife awarded patent for knitted transducer” Innovation in Textiles News: http://www.innovationintextiles.com/articles/208.php; 2pp. Aug. 2009. |
“The SmartPill Wireless Motility Capsule” SMARTPILL, The Measure of GI Health; May 2010 http://www.smartpillcorp.com/index.cfm?pagepath=Products/The_SmartPill_Capsule&id=17814. |
Solanas et al., “RFID Technology for the Health Care Sector” Recent Patents on Electrical Engineering (2008) 1, 22-31. |
Soper, S.A. et al. “Bio-Mems Technologies and Applications”, Chapter 12, “MEMS for Drug Delivery”, p. 325-346 (2007). |
Swedberg, “University Team Sees Ingestible RFID Tag as a Boon to Clinical Trials” RFID Journal Apr. 27, 2010; http://www.rfidjournal.com/article/view/7560/1, 3pp. |
Tajalli et al., “Improving the power-delay performance in subthreshold source-coupled logic circuits” Integrated Circuit and System Design. Power and Timing Modeling, Optimization and Simulation, Springer Berlin Heidelberg (2008) 21-30. |
Tatbul et al., “Confidence-based data management for personal area sensor networks” ACM International Conference Proceeding Series (2004) 72. |
Tierney, M.J. et al. “Electroreleasing Composite Membranes for Delivery of Insulin and other Biomacromolecules”, J. Electrochem. Soc., vol. 137, No. 6, Jun. 1990, p. 2005-2006. |
Trutag, Technologies, Inc., Spectral Microtags for Authentication and Anti-Counterfeiting; “Product Authentication and Brand Protection Solutions”; http://www.trutags.com/; downloaded Feb. 12, 2013 (2013); 1 pp. |
Walkey, “MOSFET Structure and Processing”; 97.398* Physical Electronics Lecture 20. |
Watson, et al., “Determination of the relationship between the pH and conductivity of gastric juice” Physiol Meas. 17 (1996) pp. 21-27. |
Winter, J. et al. “The material properties of gelatin gels”; USA Ballistic Research Laboratories, Mar. 1975, p. 1-157. |
Wongmanerod et al., “Determination of pore size distribution and surface area of thin porous silicon layers by spectroscopic ellipsometry” Applied Surface Science 172 (2001) 117-125. |
Xiaoming et al., “A telemedicine system for wireless home healthcare based on bluetooth and the internet” Telemedicine Journal and e-health (2004) 10(S2): S110-6. |
Yang et al., “Fast-switching frequency synthesizer with a discriminator-aided phase detector” IEEE Journal of Solid-State Circuits (2000) 35(10): 1445-52. |
Yao et al., “Low Power Digital Communication in Implantable Devices Using Volume Conduction of Biological Tissues” Proceedings of the 28th IEEE, EMBS Annual International Conference, Aug. 30-Sep. 3, 2006. |
Zimmerman, “Personal Area Networks: Near-field intrabody communication” IBM Systems Journal (1996) 35 (3-4):609-17. |
Zworkin, “A Radio Pill” Nature, (1957) 898, 179 Nature Publishing Group. |
Van der Biest, O., et al., “Electrophoretic deposition of materials,” Annu. Rev. Mater. Sci. 1999, 29: pp. 327-352. |
Aronson, J., “Meyer's Side Effects of Cardiovascular Drugs,” Elsevier, Mar. 2, 2009, Medical, 840 pages. (Not Attached). |
Chan, Adrian D.C., et al.; “Wavelet Distance Measure for Person Identification Using Electrocardiograms,” IEEE Transactions on Instrumentation and Measurement, IEEE Service Center, Piscataway, NJ, US, vol. 57, No. 2, Feb. 1, 2008, pp. 248-253. |
Herbig, S.M., “Asymmetric-membrane tablet coatings for osmotic drug delivery”, Journal of Controlled Release 35 (1995) 127-136. |
Lee, K. B.; “Two-step activation of paper batteries for high power generation: design and fabrication of biofluid- and wateractivated paper batteries”; J. Micromech. Microeng. 16 (2006) 2312-2317. |
Lee, K. B.; “Urine-activated paper batteries for Biosystems”; J. Micromech. Microeng. 15 (2005) S21 O-S214. |
Sammoura, F. et al., “Water-activated disposable and long shelf life microbatteries”, Sensors and Actuators A 111 (2004) 79-86. |
VonStetten, F. et al., “Biofuel cells as power generation for implantable devices”, Pore. Eurosensors XX, (2006), pp. 22-225. |
Zhang, Y-T. et al., “Wireless Biomedical Sensing,” Wiley Encyclopedia of Biomedical Engineering, 2006, pp. 1-9. |
European Search Report dated Feb. 16, 2022, issued in the corresponding European Patent Application No. 21202781.7, pp. 1-11. |
Number | Date | Country | |
---|---|---|---|
20160106339 A1 | Apr 2016 | US |
Number | Date | Country | |
---|---|---|---|
61831075 | Jun 2013 | US |